Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

Abstract

Reactive oxygen species (ROS) play a profoundly central and multifaceted role in orchestrating the complex dynamics of the tumor immune microenvironment (TIME). Oxidative stress, driven by elevated ROS levels, is considered a key regulator of tumor progression, immune cell function, and immune evasion. Although the profound impact of oxidative stress on initial oncogenesis and cellular proliferation is extensively documented, its specific contribution to TIME remodeling and subsequent immune escape warrants further investigation. This review systematically summarizes the core mechanisms of ROS and oxidative stress in the TIME. We elucidate how dysregulated ROS, generated by both malignant tumor cells and infiltrating immune populations, synergistically promote continuous tumor progression, profound local immunosuppression, and pervasive therapy resistance. Specifically, we discuss in detail how sustained oxidative stress critically alters diverse immune cell functions, fundamentally reshaping the TIME landscape, and explore oxidative stress–mediated intercellular communication networks, including metabolic competition and the release of soluble factors. By strategically bridging fundamental redox biology with emerging clinical oncology applications, this review provides novel therapeutic perspectives on modulating redox homeostasis to effectively reverse immunosuppression and bolster anti-tumor immunity.

Keywords

immune suppression / metabolic reprogramming / oxidative stress / tumor immune microenvironment

References

[1] S. Paget, “The Distribution of Secondary Growths in Cancer of the Breast,” Lancet 133, no. 3421 (1889): 571–573.

[2] L. Xu, C. Zou, S. Zhang, et al., “Reshaping the Systemic Tumor Immune Environment (STIE) and Tumor Immun E Microenvironment (TIME) to Enhance Immunotherapy Efficacy in Solid Tomors,” Journal of Hematology & Oncology 15, no. 1 (2022): 87.

[3] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The Next Generation,” Cell 144, no. 5 (2011): 646–674.

[4] M. A. Harris, P. Savas, B. Virassamy, et al., “Towards Targeting the Breast Cancer Immune Microenvironment,” Nature Reviews Cancer 24, no. 8 (2024): 554–577.

[5] H. Sies, V. V. Belousov, N. S. Chandel, et al., “Defining Roles of Specific Reactive Oxygen Species (ROS) in Cell Biology and Physiology,” Nature Reviews Molecular Cell Biology 23, no. 7 (2022): 499–515.

[6] C. Glorieux, S. Liu, D. Trachootham, and P. Huang, “Targeting ROS in Cancer: Rationale and Strategies,” Nature Reviews Drug Discovery 23, no. 8 (2024): 583–606.

[7] E. C. Cheung and K. H. Vousden, “The Role of ROS in Tumour Development and Progression,” Nature Reviews Cancer 22, no. 5 (2022): 280–297.

[8] H. Sies, R. J. Mailloux, and U. Jakob, “Fundamentals of Redox Regulation in Biology,” Nature Reviews Molecular Cell Biology 25, no. 9 (2024): 701–719.

[9] L. Wang and C. Wang, “Oxidative Protein Folding Fidelity and Redoxtasis in the Endoplasmic Reticulum,” Trends in Biochemical Sciences 48, no. 1 (2023): 40–52.

[10] K. Wu, A. E. El Zowalaty, V. I. Sayin, and T. Papagiannakopoulos, “The Pleiotropic Functions of Reactive Oxygen Species in Cancer,” Nature Cancer 5, no. 3 (2024): 384–399.

[11] B. R. Stockwell, “Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications,” Cell 185, no. 14 (2022): 2401–2421.

[12] D. D. Zhang, “Thirty Years of NRF2: Advances and Therapeutic Challenges,” Nature Reviews Drug Discovery 24, no. 6 (2025): 421–444.

[13] C. Wiel, K. Le Gal, M. X. Ibrahim, et al., “BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis,” Cell 178, no. 2 (2019): 330–345.e22.

[14] R. Pillai, M. Hayashi, A.-M. Zavitsanou, and T. Papagiannakopoulos, “NRF2: KEAPing Tumors Protected,” Cancer Discovery 12, no. 3 (2022): 625–643.

[15] B. Goretzki, M. Khoshouei, M. Schröder, et al., “Dual BACH1 Regulation by Complementary SCF-Type E3 Ligases,” Cell 187, no. 26 (2024): 7585–7602.e25.

[16] M. Yamamoto, T. W. Kensler, and H. Motohashi, “The KEAP1-NRF2 System: A Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis,” Physiological Reviews 98, no. 3 (2018): 1169–1203.

[17] J. Sun, M. Brand, Y. Zenke, S. Tashiro, M. Groudine, and K. Igarashi, “Heme Regulates the Dynamic Exchange of Bach1 and NF-E2-Related Factors in the Maf Transcription Factor Network,” Proceedings of the National Academy of Sciences 101, no. 6 (2004): 1461–1466.

[18] L. Lignitto, S. E. LeBoeuf, H. Homer, et al., “Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1,” Cell 178, no. 2 (2019): 316–329.e18.

[19] S. Hu, J. Feng, M. Wang, et al., “Nrf1 Is an Indispensable Redox-Determining Factor for Mitochondrial Homeostasis by Integrating Multi-Hierarchical Regulatory Networks,” Redox Biology 57 (2022): 102470.

[20] J. D. Hayes, A. T. Dinkova-Kostova, and K. D. Tew, “Oxidative Stress in Cancer,” Cancer Cell 38, no. 2 (2020): 167–197.

[21] Y. Zhang, Y. Xu, W. Lu, et al., “G6PD-Mediated Increase in De Novo NADP⁺ Biosynthesis Promotes Antioxidant Defense and Tumor Metastasis,” Science Advances 8, no. 29 (2022): eabo0404.

[22] Y. Zhang, Y. Xu, W. Lu, et al., “Upregulation of Antioxidant Capacity and Nucleotide Precursor Availability Suffices for Oncogenic Transformation,” Cell Metabolism 33, no. 1 (2021): 94–109.

[23] Y.-C. Chai and J. J. Mieyal, “Glutathione and Glutaredoxin—Key Players in Cellular Redox Homeostasis and Signaling,” Antioxidants 12, no. 8 (2023): 1553.

[24] L. Kennedy, J. K. Sandhu, M.-E. Harper, and M. Cuperlovic-Culf, “Role of Glutathione in Cancer: From Mechanisms to Therapies,” Biomolecules 10, no. 10 (2020): 1429.

[25] N. A. Rashdan, B. Shrestha, and C. B. Pattillo, “S-Glutathionylation, Friend or Foe in Cardiovascular Health and Disease,” Redox Biology 37 (2020): 101693.

[26] S. K. Georgiou-Siafis and A. S. Tsiftsoglou, “The Key Role of GSH in Keeping the Redox Balance in Mammalian Cells: Mechanisms and Significance of GSH in Detoxification via Formation of Conjugates,” Antioxidants 12, no. 11 (2023): 1953.

[27] Y.-A. Shen, J. Hong, R. Asaka, et al., “Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers,” Cancer Research 80, no. 20 (2020): 4514–4526.

[28] A. Bansal and M. C. Simon, “Glutathione Metabolism in Cancer Progression and Treatment Resistance,” Journal of Cell Biology 217, no. 7 (2018): 2291–2298.

[29] Y. Yan, H. Teng, Q. Hang, et al., “SLC7A11 Expression Level Dictates Differential Responses to Oxidative Stress in Cancer Cells,” Nature Communications 14, no. 1 (2023): 3673.

[30] P. Koppula, L. Zhuang, and B. Gan, “Cystine Transporter SLC7A11/xCT in Cancer: Ferroptosis, Nutrient Dependency, and Cancer Therapy,” Protein & Cell 12, no. 8 (2020): 599–620.

[31] D. Tang, X. Chen, R. Kang, and G. Kroemer, “Ferroptosis: Molecular Mechanisms and Health Implications,” Cell Research 31, no. 2 (2020): 107–125.

[32] J. K. M. Lim, A. Delaidelli, S. W. Minaker, et al., “Cystine/Glutamate Antiporter xCT (SLC7A11) Facilitates Oncogenic RAS Transformation by Preserving Intracellular Redox Balance,” Proceedings of the National Academy of Sciences 116, no. 19 (2019): 9433–9442.

[33] K. Hu, K. Li, J. Lv, et al., “Suppression of the SLC7A11/Glutathione Axis Causes Synthetic Lethality in KRAS-Mutant Lung Adenocarcinoma,” Journal of Clinical Investigation 130, no. 4 (2020): 1752–1766.

[34] H. Zhang, G. Shan, M. Liu, et al., “Harnessing ROS Amplification and GSH Depletion Using a Carrier-Free Nanodrug to Enhance Ferroptosis-Based Cancer Therapy,” Small 21, no. 6 (2024): e2409250.

[35] S. E. LeBoeuf, W. L. Wu, T. R. Karakousi, et al., “Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-Essential Amino Acids,” Cell Metabolism 31, no. 2 (2020): 339–350.e4.

[36] J. Zhang, X. Li, X. Han, R. Liu, and J. Fang, “Targeting the Thioredoxin System for Cancer Therapy,” Trends in Pharmacological Sciences 38, no. 9 (2017): 794–808.

[37] A. Zeida, M. Trujillo, G. Ferrer-Sueta, A. Denicola, D. A. Estrin, and R. Radi, “Catalysis of Peroxide Reduction by Fast Reacting Protein Thiols,” Chemical Reviews 119, no. 19 (2019): 10829–10855.

[38] I. S. Harris, A. E. Treloar, S. Inoue, et al., “Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression,” Cancer Cell 27, no. 2 (2015): 211–222.

[39] Y. J. Lee, “Knockout Mouse Models for Peroxiredoxins,” Antioxidants 9, no. 2 (2020): 182.

[40] B. Biteau, J. Labarre, and M. B. Toledano, “ATP-Dependent Reduction of Cysteine–Sulphinic Acid by S. Cerevisiae Sulphiredoxin,” Nature 425, no. 6961 (2003): 980–984.

[41] S. G. Rhee, W. Jeong, T. S. Chang, and H. A. Woo, “Sulfiredoxin, the Cysteine Sulfinic Acid Reductase Specific to 2-Cys Peroxiredoxin: Its Discovery, Mechanism of Action, and Biological Significance,” Kidney International 72 (2007): S3–S8.

[42] P. E. Molinari, A. R. Krapp, A. Weiner, et al., “NERNST: A Genetically-Encoded Ratiometric Non-Destructive Sensing Tool to Estimate NADP(H) Redox Status in Bacterial, Plant and Animal Systems,” Nature Communications 14, no. 1 (2023): 3277.

[43] H. N. Kirkman and G. F. Gaetani, “Mammalian Catalase: A Venerable Enzyme With New Mysteries,” Trends in Biochemical Sciences 32, no. 1 (2007): 44–50.

[44] L. Chen, Z. Zhang, A. Hoshino, et al., “NADPH Production by the Oxidative Pentose-Phosphate Pathway Supports Folate Metabolism,” Nature Metabolism 1, no. 3 (2019): 404–415.

[45] T. TeSlaa, M. Ralser, J. Fan, and J. D. Rabinowitz, “The Pentose Phosphate Pathway in Health and Disease,” Nature Metabolism 5, no. 8 (2023): 1275–1289.

[46] J. Whitburn, S. R. Rao, E. V. Morris, et al., “Metabolic Profiling of Prostate Cancer in Skeletal Microenvironments Identifies G6PD as a Key Mediator of Growth and Survival,” Science Advances 8, no. 8 (2022): eabf9096.

[47] R. Lin, S. Elf, C. Shan, et al., “6-Phosphogluconate Dehydrogenase Links Oxidative PPP, Lipogenesis and Tumour Growth by Inhibiting LKB1–AMPK Signalling,” Nature Cell Biology 17, no. 11 (2015): 1484–1496.

[48] M. Li, X. He, W. Guo, et al., “Aldolase B Suppresses Hepatocellular Carcinogenesis by Inhibiting G6PD and Pentose Phosphate Pathways,” Nature Cancer 1, no. 7 (2020): 735–747.

[49] T. Lan, S. Arastu, J. Lam, et al., “Glucose-6-Phosphate Dehydrogenase Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer,” Nature Communications 15, no. 1 (2024): 5857.

[50] M. P. Dore, A. Davoli, N. Longo, G. Marras, and G. M. Pes, “Glucose-6-Phosphate Dehydrogenase Deficiency and Risk of Colorectal Cancer in Northern Sardinia,” Medicine 95, no. 44 (2016): e5254.

[51] M. Li, X. Zhao, H. Yong, et al., “Transketolase Promotes Colorectal Cancer Metastasis Through Regulating AKT Phosphorylation,” Cell Death & Disease 13, no. 2 (2022): 99.

[52] G. Hoxhaj, I. Ben-Sahra, S. E. Lockwood, et al., “Direct Stimulation of NADP⁺ Synthesis Through Akt-Mediated Phosphorylation of NAD Kinase,” Science 363, no. 6431 (2019): 1088–1092.

[53] J. Du, M. Estrella, K. Solorio-Kirpichyan, P. D. Jeffrey, and A. Korennykh, “Structure of Human NADK2 Reveals Atypical Assembly and Regulation of NAD Kinases From Animal Mitochondria,” Proceedings of the National Academy of Sciences 119, no. 26 (2022): e2200923119.

[54] X. Zou, Y. Zhu, S.-H. Park, et al., “SIRT3-Mediated Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth,” Cancer Research 77, no. 15 (2017): 3990–3999.

[55] Y. Zhu, L. Gu, X. Lin, et al., “Dynamic Regulation of ME1 Phosphorylation and Acetylation Affects Lipid Metabolism and Colorectal Tumorigenesis,” Molecular Cell 77, no. 1 (2020): 138–149.

[56] J. Fan, J. Ye, J. J. Kamphorst, T. Shlomi, C. B. Thompson, and J. D. Rabinowitz, “Quantitative Flux Analysis Reveals Folate-Dependent NADPH Production,” Nature 510, no. 7504 (2014): 298–302.

[57] D. Talwar, C. G. Miller, J. Grossmann, et al., “The GAPDH Redox Switch Safeguards Reductive Capacity and Enables Survival of Stressed Tumour Cells,” Nature Metabolism 5, no. 4 (2023): 660–676.

[58] S.-M. Jeon, N. S. Chandel, and N. Hay, “AMPK Regulates NADPH Homeostasis to Promote Tumour Cell Survival During Energy Stress,” Nature 485, no. 7400 (2012): 661–665.

[59] H. Teng, Q. Hang, C. Zheng, et al., “In Vivo CRISPR Activation Screen Identifies Acyl-CoA–Binding Protein as a Driver of Bone Metastasis,” Science Translational Medicine 17, no. 799 (2025): eado7225.

[60] T. Weiss-Sadan, M. Ge, M. Hayashi, et al., “NRF2 Activation Induces NADH-Reductive Stress, Providing a Metabolic Vulnerability in Lung Cancer,” Cell Metabolism 35, no. 3 (2023): 487–503.

[61] X. Pan, X. Song, C. Wang, et al., “H2Se Induces Reductive Stress in HepG2 Cells and Activates Cell Autophagy by Regulating the Redox of HMGB1 Protein Under Hypoxia,” Theranostics 9, no. 6 (2019): 1794–1808.

[62] X. Zhai, R. Yang, Q. Chu, et al., “AMPK-Regulated Glycerol Excretion Maintains Metabolic Crosstalk Between Reductive and Energetic Stress,” Nature Cell Biology 27, no. 1 (2025): 141–153.

[63] C. Lennicke and H. M. Cochemé, “Redox Metabolism: ROS as Specific Molecular Regulators of Cell Signaling and Function,” Molecular Cell 81, no. 18 (2021): 3691–3707.

[64] B. N. Gantner, F. R. Palma, C. Kayzuka, et al., “Histone Oxidation as a New Mechanism of Metabolic Control Over Gene Expression,” Trends in Genetics 40, no. 9 (2024): 739–746.

[65] S. Lee and T. J. Kim, “ROS-Induced Metabolic Reprogramming to One-Carbon Metabolism and S-Adenosylmethionine-Mediated Epigenetic Modification in IL-10-Producing B Cells for the Resolution of Pneumonia,” Cellular & Molecular Immunology 21, no. 2 (2024): 203–204.

[66] Y. Wang, H. Qi, Y. Liu, et al., “The Double-Edged Roles of ROS in Cancer Prevention and Therapy,” Theranostics 11, no. 10 (2021): 4839–4857.

[67] J. Y. Hahm, J. Park, E.-S. Jang, and S. W. Chi, “8-Oxoguanine: From Oxidative Damage to Epigenetic and Epitranscriptional Modification,” Experimental & Molecular Medicine 54, no. 10 (2022): 1626–1642.

[68] U. S. Srinivas, B. W. Q. Tan, B. A. Vellayappan, and A. D. Jeyasekharan, “ROS and the DNA Damage Response in Cancer,” Redox Biology 25 (2019): 101084.

[69] C. Cordero, K. P. M. Mehta, T. M. Weaver, et al., “Contributing Factors to the Oxidation-Induced Mutational Landscape in Human Cells,” Nature Communications 15, no. 1 (2024): 10722.

[70] C. Majumdar, M. Demir, S. R. Merrill, M. Hashemian, and S. S. David, “FSHing for DNA Damage: Key Features of MutY Detection of 8-Oxoguanine:Adenine Mismatches,” Accounts of Chemical Research 57, no. 7 (2024): 1019–1031.

[71] M. Michel, C. Benítez-Buelga, P. A. Calvo, et al., “Small-Molecule Activation of OGG1 Increases Oxidative DNA Damage Repair by Gaining a New Function,” Science 376, no. 6600 (2022): 1471–1476.

[72] L. Y. Chang, M. Z. Lee, Y. Wu, et al., “Gene Set Correlation Enrichment Analysis for Interpreting and Annotating Gene Expression Profiles,” Nucleic Acids Research 52, no. 3 (2024): e17.

[73] Q. Huang, Y. Jing, L. Xiong, L. Li, J. Feng, and J. Cheng, “The Interplay Between Driver Mutation and Oxidative Stress in Colorectal Cancer: From Pathogenesis to Therapeutics,” Journal of Translational Medicine 23, no. 1 (2025): 635.

[74] F. Weinberg, R. Hamanaka, W. W. Wheaton, et al., “Mitochondrial Metabolism and ROS Generation Are Essential for Kras-Mediated Tumorigenicity,” Proceedings of the National Academy of Sciences 107, no. 19 (2010): 8788–8793.

[75] H. Sies, “Hydrogen Peroxide as a Central Redox Signaling Molecule in Physiological Oxidative Stress: Oxidative Eustress,” Redox Biology 11 (2017): 613–619.

[76] K. T. Schjoldager, Y. Narimatsu, H. J. Joshi, and H. Clausen, “Global View of Human Protein Glycosylation Pathways and Functions,” Nature Reviews Molecular Cell Biology 21, no. 12 (2020): 729–749.

[77] C. T. Walsh, S. Garneau-Tsodikova, and G. J. Gatto, “Protein Posttranslational Modifications: The Chemistry of Proteome Diversifications,” Angewandte Chemie International Edition 44, no. 45 (2005): 7342–7372.

[78] X. Guo, J. Zhong, J. Qian, et al., “tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression,” Cancer Research 85, no. 23 (2025): 4787–4805.

[79] B. L. Hopkins and C. A. Neumann, “Redoxins as Gatekeepers of the Transcriptional Oxidative Stress Response,” Redox Biology 21 (2019): 101104.

[80] Y. Wei, M. Lu, M. Mei, et al., “Pyridoxine Induces Glutathione Synthesis via PKM2-Mediated Nrf2 Transactivation and Confers Neuroprotection,” Nature Communications 11, no. 1 (2020): 941.

[81] J. T. Jones, X. Qian, J. L. J. van der Velden, et al., “Glutathione S-Transferase Pi Modulates NF-κB Activation and Pro-Inflammatory Responses in Lung Epithelial Cells,” Redox Biology 8 (2016): 375–382.

[82] R. J. Mailloux and J. R. Treberg, “Protein S-Glutathionlyation Links Energy Metabolism to Redox Signaling in Mitochondria,” Redox Biology 8 (2016): 110–118.

[83] X. Sun, C. Guo, C. Huang, et al., “GSTP Alleviates Acute Lung Injury by S-Glutathionylation of KEAP1 and Subsequent Activation of NRF2 Pathway,” Redox Biology 71 (2024): 103116.

[84] A. Chatterjee and S. Gupta, “The Multifaceted Role of Glutathione S-Transferases in Cancer,” Cancer Letters 433 (2018): 33–42.

[85] D. He, H. Feng, B. Sundberg, et al., “Methionine Oxidation Activates Pyruvate Kinase M2 to Promote Pancreatic Cancer Metastasis,” Molecular Cell 82, no. 16 (2022): 3045–3060.e11.

[86] S. X. Gu, J. W. Stevens, and S. R. Lentz, “Regulation of Thrombosis and Vascular Function by Protein Methionine Oxidation,” Blood 125, no. 25 (2015): 3851–3859.

[87] S. S. Mortazavi Farsani, J. Soni, L. Jin, et al., “Pyruvate Kinase M2 Activation Reprograms Mitochondria in CD8 T Cells, Enhancing Effector Functions and Efficacy of Anti-PD1 Therapy,” Cell Metabolism 37, no. 6 (2025): 1294–1310.e7.

[88] U. Topf, I. Suppanz, L. Samluk, et al., “Quantitative Proteomics Identifies Redox Switches for Global Translation Modulation by Mitochondrially Produced Reactive Oxygen Species,” Nature Communications 9, no. 1 (2018): 324.

[89] J. Meng, L. Fu, K. Liu, et al., “Global Profiling of Distinct Cysteine Redox Forms Reveals Wide-Ranging Redox Regulation in C. elegans,” Nature Communications 12, no. 1 (2021): 1415.

[90] J. Zuo, Z. Zhang, M. Li, et al., “The Crosstalk Between Reactive Oxygen Species and Noncoding RNAs: From Cancer Code to Drug Role,” Molecular Cancer 21, no. 1 (2022): 30.

[91] S. Liu, Y. Qiu, R. Xiang, and P. Huang, “Characterization of H₂O₂-Induced Alterations in Global Transcription of mRNA and lncRNA,” Antioxidants 11, no. 3 (2022): 495.

[92] J. D. Hayes, S. Dayalan Naidu, and A. T. Dinkova-Kostova, “Regulating Nrf2 Activity: Ubiquitin Ligases and Signaling Molecules in Redox Homeostasis,” Trends in Biochemical Sciences 50, no. 3 (2025): 179–205.

[93] H.-S. Li, Y.-N. Zhou, L. Li, et al., “HIF-1α Protects Against Oxidative Stress by Directly Targeting Mitochondria,” Redox Biology 25 (2019): 101109.

[94] G. Calissi, E. W. F. Lam, and W. Link, “Therapeutic Strategies Targeting FOXO Transcription Factors,” Nature Reviews Drug Discovery 20, no. 1 (2020): 21–38.

[95] Z. Xin, C. Hu, C. Zhang, et al., “LncRNA-HMG Incites Colorectal Cancer Cells to Chemoresistance via Repressing p53-Mediated Ferroptosis,” Redox Biology 77 (2024): 103362.

[96] K. Yuan, J. Lan, L. Xu, et al., “Long Noncoding RNA TLNC1 Promotes the Growth and Metastasis of Liver Cancer via Inhibition of p53 Signaling,” Molecular Cancer 21, no. 1 (2022): 105.

[97] Z. Huang, J.-K. Zhou, Y. Peng, W. He, and C. Huang, “The Role of Long Noncoding RNAs in Hepatocellular Carcinoma,” Molecular Cancer 19, no. 1 (2020): 77.

[98] Y. Lv, Y. Lv, Z. Wang, K. Yuan, and Y. Zeng, “Noncoding RNAs as Sensors of Tumor Microenvironmental Stress,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022): 224.

[99] F. Long, Z. Lin, L. Li, et al., “Comprehensive Landscape and Future Perspectives of Circular RNAs in Colorectal Cancer,” Molecular Cancer 20, no. 1 (2021): 26.

[100] M. Yu, T. Ozaki, D. Sun, et al., “HIF-1α-Dependent miR-424 Induction Confers Cisplatin Resistance on Bladder Cancer Cells Through Down-Regulation of Pro-Apoptotic UNC5B and SIRT4,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020): 108.

[101] G. Cavalli and E. Heard, “Advances in Epigenetics Link Genetics to the Environment and Disease,” Nature 571, no. 7766 (2019): 489–499.

[102] A. Kinnaird, S. Zhao, K. E. Wellen, and E. D. Michelakis, “Metabolic Control of Epigenetics in Cancer,” Nature Reviews Cancer 16, no. 11 (2016): 694–707.

[103] J.-L. García-Giménez, C. Garcés, C. Romá-Mateo, and F. V. Pallardó, “Oxidative Stress-Mediated Alterations in Histone Post-Translational Modifications,” Free Radical Biology and Medicine 170 (2021): 6–18.

[104] S. Zhao, C. D. Allis, and G. G. Wang, “The Language of Chromatin Modification in Human Cancers,” Nature Reviews Cancer 21, no. 7 (2021): 413–430.

[105] B. R. Sabari, D. Zhang, C. D. Allis, and Y. Zhao, “Metabolic Regulation of Gene Expression Through Histone Acylations,” Nature Reviews Molecular Cell Biology 18, no. 2 (2016): 90–101.

[106] A. L. Mattei, N. Bailly, and A. Meissner, “DNA Methylation: A Historical Perspective,” Trends in Genetics 38, no. 7 (2022): 676–707.

[107] Y. Zhao, X. Fan, Q. Wang, et al., “ROS Promote Hyper-Methylation of NDRG2 Promoters in a DNMTS-Dependent Manner: Contributes to the Progression of Renal Fibrosis,” Redox Biology 62 (2023): 102674.

[108] Y. Lee, K. H. Vousden, and M. Hennequart, “Cycling Back to Folate Metabolism in Cancer,” Nature Cancer 5, no. 5 (2024): 701–715.

[109] F. J. de Miguel, C. Gentile, W. W. Feng, et al., “Mammalian SWI/SNF Chromatin Remodeling Complexes Promote Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Lung Cancer,” Cancer Cell 41, no. 8 (2023): 1516–1534.e9.

[110] S. Eom, J. Peak, J. Park, et al., “Widespread 8-Oxoguanine Modifications of miRNA Seeds Differentially Regulate Redox-Dependent Cancer Development,” Nature Cell Biology 25, no. 9 (2023): 1369–1383.

[111] A. Cappannini, A. Ray, E. Purta, et al., “MODOMICS: A Database of RNA Modifications and Related Information. 2023 Update,” Nucleic Acids Research 52, no. D1 (2024): D239–D244.

[112] Y. Du, G. Hou, H. Zhang, et al., “SUMOylation of the m6A-RNA Methyltransferase METTL3 Modulates Its Function,” Nucleic Acids Research 46, no. 10 (2018): 5195–5208.

[113] J. Qu, H. Yan, Y. Hou, et al., “RNA Demethylase ALKBH5 in Cancer: From Mechanisms to Therapeutic Potential,” Journal of Hematology & Oncology 15, no. 1 (2022): 8.

[114] Y. Ma, J. Guo, H. Rao, et al., “The 8-Oxoguanine DNA Glycosylase-Synaptotagmin 7 Pathway Increases Extracellular Vesicle Release and Promotes Tumour Metastasis During Oxidative Stress,” Journal of Extracellular Vesicles 13, no. 9 (2024): e12505.

[115] B. He, Z. Huang, S. Qin, et al., “Enhanced SLC35B2/SAV1 Sulfation Axis Promotes Tumor Growth by Inhibiting Hippo Signaling in HCC,” Hepatology 81, no. 2 (2025): 436–452.

[116] M. J. Iqbal, A. Kabeer, Z. Abbas, et al., “Interplay of Oxidative Stress, Cellular Communication and Signaling Pathways in Cancer,” Cell Communication and Signaling 22, no. 1 (2024): 7.

[117] J. Yuan, X. Dong, J. Yap, and J. Hu, “The MAPK and AMPK Signalings: Interplay and Implication in Targeted Cancer Therapy,” Journal of Hematology & Oncology 13, no. 1 (2020): 113.

[118] J. Liu, X. Han, T. Zhang, K. Tian, Z. Li, and F. Luo, “Reactive Oxygen Species (ROS) Scavenging Biomaterials for Anti-Inflammatory Diseases: From Mechanism to Therapy,” Journal of Hematology & Oncology 16, no. 1 (2023): 116.

[119] D. W. Chan, V. W. S. Liu, G. S. W. Tsao, et al., “Loss of MKP3 Mediated by Oxidative Stress Enhances Tumorigenicity and Chemoresistance of Ovarian Cancer Cells,” Carcinogenesis 29, no. 9 (2008): 1742–1750.

[120] M. J. Morgan and Z. Liu, “Crosstalk of Reactive Oxygen Species and NF-κB Signaling,” Cell Research 21, no. 1 (2010): 103–115.

[121] Y. Ishihara, T. Takemoto, K. Itoh, A. Ishida, and T. Yamazaki, “Dual Role of Superoxide Dismutase 2 Induced in Activated Microglia,” Journal of Biological Chemistry 290, no. 37 (2015): 22805–22817.

[122] J. Choi, M. Ceribelli, J. D. Phelan, et al., “Molecular Targets of Glucocorticoids That Elucidate Their Therapeutic Efficacy in Aggressive Lymphomas,” Cancer Cell 42, no. 5 (2024): 833–849.

[123] C. A. Coughlin, D. Chahar, M. Lekakis, et al., “Bruton's Tyrosine Kinase Inhibition Re-Sensitizes Multidrug-Resistant Dlbcl Tumors Driven by BCL10 Gain-Of-Function Mutants to Venetoclax,” Blood Cancer Journal 15, no. 1 (2025): 9.

[124] C. E. Paulsen, T. H. Truong, F. J. Garcia, et al., “Peroxide-Dependent Sulfenylation of the Egfr Catalytic Site Enhances Kinase Activity,” Nature Chemical Biology 8, no. 1 (2011): 57–64.

[125] J. A. Bertout, S. A. Patel, and M. C. Simon, “The Impact of O₂ Availability on Human Cancer,” Nature Reviews Cancer 8, no. 12 (2008): 967–975.

[126] Y. Li, W. Wang, D. Xu, et al., “PIWIL2/PDK1 Axis Promotes the Progression of Cervical Epithelial Lesions via Metabolic Reprogramming to Maintain Tumor-Initiating Cell Stemness,” Advanced Science 11, no. 48 (2024): e2410756.

[127] M. Jiang, H. Fang, and H. Tian, “Metabolism of Cancer Cells and Immune Cells in the Initiation, Progression, and Metastasis of Cancer,” Theranostics 15, no. 1 (2025): 155–188.

[128] B. Faubert, A. Solmonson, and R. J. DeBerardinis, “Metabolic Reprogramming and Cancer Progression,” Science 368, no. 6487 (2020): eaaw5473.

[129] S.-M. Fendt, “100 Years of the Warburg Effect: A Cancer Metabolism Endeavor,” Cell 187, no. 15 (2024): 3824–3828.

[130] M. G. Vander Heiden, L. C. Cantley, and C. B. Thompson, “Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation,” Science 324, no. 5930 (2009): 1029–1033.

[131] I. Martínez-Reyes and N. S. Chandel, “Cancer Metabolism: Looking Forward,” Nature Reviews Cancer 21, no. 10 (2021): 669–680.

[132] M. Tufail, C.-H. Jiang, and N. Li, “Altered Metabolism in Cancer: Insights Into Energy Pathways and Therapeutic Targets,” Molecular Cancer 23, no. 1 (2024): 203.

[133] J. Lin, D. Rao, M. Zhang, and Q. Gao, “Metabolic Reprogramming in the Tumor Microenvironment of Liver Cancer,” Journal of Hematology & Oncology 17, no. 1 (2024): 6.

[134] Z. Yao, Y. Fan, L. Lin, R. E. Kellems, and Y. Xia, “Tissue Transglutaminase: A Multifunctional and Multisite Regulator in Health and Disease,” Physiological Reviews 104, no. 1 (2024): 281–325.

[135] Q. Gu, Y. Wang, P. Yi, and C. Cheng, “Theoretical Framework and Emerging Challenges of Lipid Metabolism in Cancer,” Seminars in Cancer Biology 108 (2025): 48–70.

[136] S. L. Geeraerts, E. Heylen, K. De Keersmaecker, and K. R. Kampen, “The Ins and Outs of Serine and Glycine Metabolism in Cancer,” Nature Metabolism 3, no. 2 (2021): 131–141.

[137] O. D. K. Maddocks, D. Athineos, E. C. Cheung, et al., “Modulating the Therapeutic Response of Tumours to Dietary Serine and Glycine Starvation,” Nature 544, no. 7650 (2017): 372–376.

[138] J. Liang, R. Cao, X. Wang, et al., “Mitochondrial PKM2 Regulates Oxidative Stress-Induced Apoptosis by Stabilizing Bcl2,” Cell Research 27, no. 3 (2016): 329–351.

[139] L. Wu, Y. Jin, X. Zhao, et al., “Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing via TNF-α,” Cell Metabolism 35, no. 9 (2023): 1580–1596.e9.

[140] A. Zoccarato, I. Smyrnias, C. M. Reumiller, et al., “NRF2 Activation in the Heart Induces Glucose Metabolic Reprogramming and Reduces Cardiac Dysfunction via Upregulation of the Pentose Phosphate Pathway,” Cardiovascular Research 121, no. 2 (2025): 339–352.

[141] H. Shen, O. A. Ojo, H. Ding, et al., “HIF1α-regulated Glycolysis Promotes Activation-Induced Cell Death and IFN-γ Induction in Hypoxic T Cells,” Nature Communications 15, no. 1 (2024): 9394.

[142] F. Grimm, A. Asuaje, A. Jain, et al., “Metabolic Priming by Multiple Enzyme Systems Supports Glycolysis, HIF1α Stabilisation, and Human Cancer Cell Survival in Early Hypoxia,” EMBO Journal 43, no. 8 (2024): 1545–1569.

[143] H.-R. Jin, J. Wang, Z.-J. Wang, et al., “Lipid Metabolic Reprogramming in Tumor Microenvironment: From Mechanisms to Therapeutics,” Journal of Hematology & Oncology 16, no. 1 (2023): 103.

[144] F. Röhrig and A. Schulze, “The Multifaceted Roles of Fatty Acid Synthesis in Cancer,” Nature Reviews Cancer 16, no. 11 (2016): 732–749.

[145] G. Hatzivassiliou, F. Zhao, D. E. Bauer, et al., “ATP Citrate Lyase Inhibition Can Suppress Tumor Cell Growth,” Cancer Cell 8, no. 4 (2005): 311–321.

[146] R. U. Svensson, S. J. Parker, L. J. Eichner, et al., “Inhibition of Acetyl-CoA Carboxylase Suppresses Fatty Acid Synthesis and Tumor Growth of Non-Small-Cell Lung Cancer in Preclinical Models,” Nature Medicine 22, no. 10 (2016): 1108–1119.

[147] G. Zadra, C. F. Ribeiro, P. Chetta, et al., “Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer,” Proceedings of the National Academy of Sciences 116, no. 2 (2018): 631–640.

[148] J. Zhang, F. Song, X. Zhao, et al., “EGFR Modulates Monounsaturated Fatty Acid Synthesis Through Phosphorylation of SCD1 in Lung Cancer,” Molecular Cancer 16, no. 1 (2017): 127.

[149] T. MacVicar, Y. Ohba, H. Nolte, et al., “Lipid Signalling Drives Proteolytic Rewiring of Mitochondria by YME1L,” Nature 575, no. 7782 (2019): 361–365.

[150] M. Martin-Perez, U. Urdiroz-Urricelqui, C. Bigas, and S. A. Benitah, “The Role of Lipids in Cancer Progression and Metastasis,” Cell Metabolism 34, no. 11 (2022): 1675–1699.

[151] J. Ma, S. Wang, P. Zhang, et al., “Emerging Roles for Fatty Acid Oxidation in Cancer,” Genes & Diseases 12, no. 4 (2025): 101491.

[152] Q. Qu, F. Zeng, X. Liu, Q. J. Wang, and F. Deng, “Fatty Acid Oxidation and Carnitine Palmitoyltransferase I: Emerging Therapeutic Targets in Cancer,” Cell Death & Disease 7, no. 5 (2016): e2226.

[153] T. K. Choueiri and W. G. Kaelin, “Targeting the HIF2–VEGF Axis in Renal Cell Carcinoma,” Nature Medicine 26, no. 10 (2020): 1519–1530.

[154] B. Krishnamachary, S. Berg-Dixon, B. Kelly, et al., “Regulation of Colon Carcinoma Cell Invasion by Hypoxia-Inducible Factor,” Cancer Research 63, no. 5 (2003): 1138–1143.

[155] P. Mak, I. Leav, B. Pursell, et al., “ERβ Impedes Prostate Cancer EMT by Destabilizing HIF-1α and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading,” Cancer Cell 17, no. 4 (2010): 319–332.

[156] E. B. Rankin and A. J. Giaccia, “Hypoxic Control of Metastasis,” Science 352, no. 6282 (2016): 175–180.

[157] T. M. Ashton, E. Fokas, L. A. Kunz-Schughart, et al., “The Anti-Malarial Atovaquone Increases Radiosensitivity by Alleviating Tumour Hypoxia,” Nature Communications 7, no. 1 (2016): 12308.

[158] M. Wang, J. S. Kirk, S. Venkataraman, et al., “Manganese Superoxide Dismutase Suppresses Hypoxic Induction of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor,” Oncogene 24, no. 55 (2005): 8154–8166.

[159] Y. Liu, P. Wang, W. Hu, and D. Chen, “New Insights Into the Roles of Peroxiredoxins in Cancer,” Biomedicine & Pharmacotherapy 164 (2023): 114896.

[160] J. Jin, S. Qiu, P. Wang, et al., “Cardamonin Inhibits Breast Cancer Growth by Repressing HIF-1α-Dependent Metabolic Reprogramming,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 377.

[161] S. Colla, S. Tagliaferri, F. Morandi, et al., “The New Tumor-Suppressor Gene Inhibitor of Growth Family Member 4 (ING 4) Regulates the Production of Proangiogenic Molecules by Myeloma Cell S and Suppresses Hypoxia-Inducible Factor-1 Alpha (HIF-1alpha) Activity: Involvement in Myeloma-Induced Angiogenesis,” Blood 110, no. 13 (2007): 4464–4475.

[162] K. Ghattass, S. El-Sitt, K. Zibara, et al., “The Quinoxaline Di-N-Oxide DCQ Blocks Breast Cancer Metastasis In Vitro and In Vivo by Targeting the Hypoxia Inducible Factor-1 Pathway,” Molecular Cancer 13 (2014): 12.

[163] C. Xia, Q. Meng, L.-Z. Liu, Y. Rojanasakul, X. R. Wang, and B. H. Jiang, “Reactive Oxygen Species Regulate Angiogenesis and Tumor Growth Through Vascular Endothelial Growth Factor,” Cancer Research 67, no. 22 (2007): 10823–10830.

[164] J. Mitsushita, J. D. Lambeth, and T. Kamata, “The Superoxide-Generating Oxidase Nox1 Is Functionally Required for Ras Oncogene Transformation,” Cancer Research 64, no. 10 (2004): 3580–3585.

[165] D. Komatsu, M. Kato, J. Nakayama, S. Miyagawa, and T. Kamata, “NADPH Oxidase 1 Plays a Critical Mediating Role in Oncogenic Ras-Induced Vascular Endothelial Growth Factor Expression,” Oncogene 27, no. 34 (2008): 4724–4732.

[166] K. B. Myant, P. Cammareri, E. J. McGhee, et al., “ROS Production and NF-κB Activation Triggered by RAC1 Facilitate WNT-Driven Intestinal Stem Cell Proliferation and Colorectal Cancer Initiation,” Cell Stem Cell 12, no. 6 (2013): 761–773.

[167] M. Daugaard, R. Nitsch, B. Razaghi, et al., “Hace1 Controls ROS Generation of Vertebrate Rac1-Dependent NADPH Oxidase Complexes,” Nature Communications 4, no. 1 (2013): 2180.

[168] C.-J. Lee, T.-Y. Jang, S.-E. Jeon, et al., “The Dysadherin/MMP9 Axis Modifies the Extracellular Matrix to Accelerate Colorectal Cancer Progression,” Nature Communications 15, no. 1 (2024): 10422.

[169] D. C. Radisky, D. D. Levy, L. E. Littlepage, et al., “Rac1b and Reactive Oxygen Species Mediate MMP-3-Induced EMT and Genomic Instability,” Nature 436, no. 7047 (2005): 123–127.

[170] M. L. Stallings-Mann, J. Waldmann, Y. Zhang, et al., “Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression,” Science Translational Medicine 4, no. 142 (2012): 142ra195.

[171] A. Pezone, M. L. Taddei, A. Tramontano, et al., “Targeted DNA Oxidation by LSD1–SMAD2/3 Primes TGF-β1/EMT Genes for Activation or Repression,” Nucleic Acids Research 48, no. 16 (2020): 8943–8958.

[172] X. Z. West, N. L. Malinin, A. A. Merkulova, et al., “Oxidative Stress Induces Angiogenesis by Activating TLR2 With Novel Endogenous Ligands,” Nature 467, no. 7318 (2010): 972–976.

[173] Y.-W. Kim and T. V. Byzova, “Oxidative Stress in Angiogenesis and Vascular Disease,” Blood 123, no. 5 (2014): 625–631.

[174] Y. M. Kim, K. E. Kim, G. Y. Koh, Y. S. Ho, and K. J. Lee, “Hydrogen Peroxide Produced by Angiopoietin-1 Mediates Angiogenesis,” Cancer Research 66, no. 12 (2006): 6167–6174.

[175] K. Le Gal, M. X. Ibrahim, C. Wiel, et al., “Antioxidants Can Increase Melanoma Metastasis in Mice,” Science Translational Medicine 7, no. 308 (2015): 308re8.

[176] T. Wang, Y. Dong, Z. Huang, et al., “Antioxidants Stimulate BACH1-Dependent Tumor Angiogenesis,” Journal of Clinical Investigation 133, no. 20 (2023): e169671.

[177] A. Tasdogan, B. Faubert, V. Ramesh, et al., “Metabolic Heterogeneity Confers Differences in Melanoma Metastatic Potential,” Nature 577, no. 7788 (2019): 115–120.

[178] J. R. Doherty, C. Yang, K. E. N. Scott, et al., “Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis,” Cancer Research 74, no. 3 (2014): 908–920.

[179] E. Piskounova, M. Agathocleous, M. M. Murphy, et al., “Oxidative Stress Inhibits Distant Metastasis by Human Melanoma Cells,” Nature 527, no. 7577 (2015): 186–191.

[180] J. M. Ubellacker, A. Tasdogan, V. Ramesh, et al., “Lymph Protects Metastasizing Melanoma Cells From Ferroptosis,” Nature 585, no. 7823 (2020): 113–118.

[181] C.-C. Weng, M.-J. Hsieh, C.-C. Wu, et al., “Loss of the Transcriptional Repressor TGIF1 Results in Enhanced Kras-Driven Development of Pancreatic Cancer,” Molecular Cancer 18, no. 1 (2019): 96.

[182] E. C. Cheung, G. M. DeNicola, C. Nixon, et al., “Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer,” Cancer Cell 37, no. 2 (2020): 168–182.

[183] E. C. Cheung, D. Strathdee, D. Stevenson, J. Coomes, K. Blyth, and K. H. Vousden, “Regulation of ROS Signaling by TIGAR Induces Cancer-Modulating Responses in the Tumor Microenvironment,” Proceedings of the National Academy of Sciences 121, no. 50 (2024): e2416076121.

[184] F. Geissmann, M. G. Manz, S. Jung, M. H. Sieweke, M. Merad, and K. Ley, “Development of Monocytes, Macrophages, and Dendritic Cells,” Science 327, no. 5966 (2010): 656–661.

[185] A. Mantovani, P. Allavena, F. Marchesi, and C. Garlanda, “Macrophages as Tools and Targets in Cancer Therapy,” Nature Reviews Drug Discovery 21, no. 11 (2022): 799–820.

[186] C. E. Lewis and J. W. Pollard, “Distinct Role of Macrophages in Different Tumor Microenvironments,” Cancer Research 66, no. 2 (2006): 605–612.

[187] B.-Z. Qian and J. W. Pollard, “Macrophage Diversity Enhances Tumor Progression and Metastasis,” Cell 141, no. 1 (2010): 39–51.

[188] A.-T. Henze and M. Mazzone, “The Impact of Hypoxia on Tumor-Associated Macrophages,” Journal of Clinical Investigation 126, no. 10 (2016): 3672–3679.

[189] A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-Related Inflammation,” Nature 454, no. 7203 (2008): 436–444.

[190] B. Brüne, N. Dehne, N. Grossmann, et al., “Redox Control of Inflammation in Macrophages,” Antioxidants & Redox Signaling 19, no. 6 (2013): 595–637.

[191] Y. Zhang, S. Choksi, K. Chen, Y. Pobezinskaya, I. Linnoila, and Z. G. Liu, “ROS Play a Critical Role in the Differentiation of Alternatively Activated Macrophages and the Occurrence of Tumor-Associated Macrophages,” Cell Research 23, no. 7 (2013): 898–914.

[192] H.-M. Lo, C.-L. Chen, C.-M. Yang, et al., “The Carotenoid Lutein Enhances Matrix metalloproteinase-9 Production and Phagocytosis Through Intracellular ROS Generation and ERK1/2, p38 Mapk, and RARβ Activation in Murine Macrophages,” Journal of Leukocyte Biology 93, no. 5 (2013): 723–735.

[193] C. J. Hall, R. H. Boyle, J. W. Astin, et al., “Immunoresponsive Gene 1 Augments Bactericidal Activity of Macrophage-Lineage Cells by Regulating β-Oxidation-Dependent Mitochondrial ROS Production,” Cell Metabolism 18, no. 2 (2013): 265–278.

[194] C. Roux, S. M. Jafari, R. Shinde, et al., “Reactive Oxygen Species Modulate Macrophage Immunosuppressive Phenotyp E Through the Up-Regulation of PD-L1,” Proceedings of the National Academy of Sciences 116, no. 10 (2019): 4326–4335.

[195] N. Patsoukis, Q. Wang, L. Strauss, and V. A. Boussiotis, “Revisiting the PD-1 Pathway,” Science Advances 6, no. 38 (2020): eabd2712.

[196] A. Robinson, C. Z. Han, C. K. Glass, and J. W. Pollard, “Monocyte Regulation in Homeostasis and Malignancy,” Trends in Immunology 42, no. 2 (2021): 104–119.

[197] J. Zhang, J. Muri, G. Fitzgerald, et al., “Endothelial Lactate Controls Muscle Regeneration From Ischemia by Inducing M2-like Macrophage Polarization,” Cell Metabolism 31, no. 6 (2020): 1136–1153.

[198] P. Guermonprez, J. Valladeau, L. Zitvogel, C. Théry, and S. Amigorena, “Antigen Presentation and T Cell Stimulation by Dendritic Cells,” Annual Review of Immunology 20 (2002): 621–667.

[199] E. S. Trombetta and I. Mellman, “Cell Biology of Antigen Processing In Vitro and In Vivo,” Annual Review of Immunology 23 (2005): 975–1028.

[200] G. J. Randolph, V. Angeli, and M. A. Swartz, “Dendritic-Cell Trafficking to Lymph Nodes Through Lymphatic Vessels,” Nature Reviews Immunology 5, no. 8 (2005): 617–628.

[201] B. Pulendran, J. L. Smith, G. Caspary, et al., “Distinct Dendritic Cell Subsets Differentially Regulate the Class of Immune Response In Vivo,” Proceedings of the National Academy of Sciences 96, no. 3 (1999): 1036–1041.

[202] R. Maldonado-López, T. De Smedt, P. Michel, et al., “CD8α⁺ and CD8α⁻ Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo,” Journal of Experimental Medicine 189, no. 3 (1999): 587–592.

[203] R. A. Seder, W. E. Paul, M. M. Davis, and B. Fazekas de St Groth, “The Presence of Interleukin 4 During in Vitro Priming Determines the Lymphokine-Producing Potential of CD4⁺ T Cells From T Cell Receptor Transgenic Mice,” Journal of Experimental Medicine 176, no. 4 (1992): 1091–1098.

[204] S. LeibundGut-Landmann, O. Groß, M. J. Robinson, et al., “Syk- and CARD9-Dependent Coupling of Innate Immunity to the Induction of T Helper Cells That Produce Interleukin 17,” Nature Immunology 8, no. 6 (2007): 630–638.

[205] H. Jonuleit, E. Schmitt, G. Schuler, J. Knop, and A. H. Enk, “Induction of Interleukin 10–Producing, Nonproliferating Cd4⁺ T Cells With Regulatory Properties by Repetitive Stimulation With Allogeneic Immature Human Dendritic Cells,” Journal of Experimental Medicine 192, no. 9 (2000): 1213–1222.

[206] X. Luo, K. V. Tarbell, H. Yang, et al., “Dendritic Cells With TGF-β1 Differentiate Naïve CD4⁺CD25⁻ T Cells Into Islet-Protective Foxp3⁺regulatory T Cells,” Proceedings of the National Academy of Sciences 104, no. 8 (2007): 2821–2826.

[207] V. P. Badovinac, K. A. N. Messingham, A. Jabbari, J. S. Haring, and J. T. Harty, “Accelerated CD8⁺ T-Cell Memory and Prime-Boost Response After Dendritic-Cell Vaccination,” Nature Medicine 11, no. 7 (2005): 748–756.

[208] H. C. Probst, K. McCoy, T. Okazaki, T. Honjo, and M. van den Broek, “Resting Dendritic Cells Induce Peripheral CD8⁺ T Cell Tolerance Through PD-1 and CTLA-4,” Nature Immunology 6, no. 3 (2005): 280–286.

[209] R. L. Lindquist, G. Shakhar, D. Dudziak, et al., “Visualizing Dendritic Cell Networks In Vivo,” Nature Immunology 5, no. 12 (2004): 1243–1250.

[210] J. H. Niess, S. Brand, X. Gu, et al., “CX3CR1-Mediated Dendritic Cell Access to the Intestinal Lumen and Bacterial Clearance,” Science 307, no. 5707 (2005): 254–258.

[211] C. Reis e Sousa, “Dendritic Cells in a Mature Age,” Nature Reviews Immunology 6, no. 6 (2006): 476–483.

[212] D. Dudziak, A. O. Kamphorst, G. F. Heidkamp, et al., “Differential Antigen Processing by Dendritic Cell Subsets In Vivo,” Science 315, no. 5808 (2007): 107–111.

[213] K. Shortman and S. H. Naik, “Steady-State and Inflammatory Dendritic-Cell Development,” Nature Reviews Immunology 7, no. 1 (2006): 19–30.

[214] S. Kantengwa, L. Jornot, C. Devenoges, and L. P. Nicod, “Superoxide Anions Induce the Maturation of Human Dendritic Cells,” American Journal of Respiratory and Critical Care Medicine 167, no. 3 (2003): 431–437.

[215] M. Oberkampf, C. Guillerey, J. Mouriès, et al., “Mitochondrial Reactive Oxygen Species Regulate the Induction of Cd8⁺ T Cells by Plasmacytoid Dendritic Cells,” Nature Communications 9, no. 1 (2018): 2241.

[216] M. Rescigno, M. Martino, C. L. Sutherland, M. R. Gold, and P. Ricciardi-Castagnoli, “Dendritic Cell Survival and Maturation Are Regulated by Different Signaling Pathways,” Journal of Experimental Medicine 188, no. 11 (1998): 2175–2180.

[217] J. R. Cubillos-Ruiz, P. C. Silberman, M. R. Rutkowski, et al., “ER Stress Sensor XBP1 Controls Anti-Tumor Immunity by Disrupting Dendritic Cell Homeostasis,” Cell 161, no. 7 (2015): 1527–1538.

[218] E. Vivier, D. Artis, M. Colonna, et al., “Innate Lymphoid Cells: 10 Years On,” Cell 174, no. 5 (2018): 1054–1066.

[219] N. Jacquelot, C. Seillet, E. Vivier, and G. T. Belz, “Innate Lymphoid Cells and Cancer,” Nature Immunology 23, no. 3 (2022): 371–379.

[220] X. Su, Z. Deng, Y. Lan, B. Liu, and C. Liu, “Helper ILCs in the Human Hematopoietic System,” Trends in Immunology 46, no. 3 (2025): 244–257.

[221] Z. Li, R. Ma, H. Tang, et al., “Therapeutic Application of Human Type 2 Innate Lymphoid Cells via Induction of Granzyme B-Mediated Tumor Cell Death,” Cell 187, no. 3 (2024): 624–641.e23.

[222] Z. Li, R. Ma, S. Ma, et al., “ILC1s Control Leukemia Stem Cell Fate and Limit Development of AML,” Nature Immunology 23, no. 5 (2022): 718–730.

[223] L. Ducimetière, G. Lucchiari, G. Litscher, et al., “Conventional NK Cells and Tissue-Resident ILC1s Join Forces to Control Liver Metastasis,” Proceedings of the National Academy of Sciences 118, no. 27 (2021): e2026271118.

[224] J. A. Moral, J. Leung, L. A. Rojas, et al., “ILC2s Amplify PD-1 Blockade by Activating Tissue-Specific Cancer Immunity,” Nature 579, no. 7797 (2020): 130–135.

[225] J. Kim, W. Kim, U. J. Moon, et al., “Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth,” Journal of Immunology 196, no. 5 (2016): 2410–2423.

[226] P. Carrega, F. Loiacono, E. Di Carlo, et al., “NCR⁺ILC3 Concentrate in Human Lung Cancer and Associate With Intratumoral Lymphoid Structures,” Nature Communications 6, no. 1 (2015): 8280.

[227] S. Wang, Y. Qu, P. Xia, et al., “Transdifferentiation of Tumor Infiltrating Innate Lymphoid Cells During Progression of Colorectal Cancer,” Cell Research 30, no. 7 (2020): 610–622.

[228] J. Koh, H. Y. Kim, Y. Lee, et al., “IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) Into ILC3,” Clinical Cancer Research 25, no. 13 (2019): 4026–4037.

[229] J. Goc, M. Lv, N. J. Bessman, et al., “Dysregulation of ILC3s Unleashes Progression and Immunotherapy Resistance in Colon Cancer,” Cell 184, no. 19 (2021): 5015–5030.e16.

[230] S. Trabanelli, M. F. Chevalier, A. Martinez-Usatorre, et al., “Tumour-Derived PGD2 and NKp30-B7H6 Engagement Drives an Immunosuppressive ILC2-MDSC Axis,” Nature Communications 8, no. 1 (2017): 593.

[231] M. F. Chevalier, S. Trabanelli, J. Racle, et al., “ILC2-modulated T Cell–To-MDSC Balance Is Associated With Bladder Cancer Recurrence,” Journal of Clinical Investigation 127, no. 8 (2017): 2916–2929.

[232] S. Kirchberger, D. J. Royston, O. Boulard, et al., “Innate Lymphoid Cells Sustain Colon Cancer Through Production of Interleukin-22 in a Mouse Model,” Journal of Experimental Medicine 210, no. 5 (2013): 917–931.

[233] B. Ruf, T. F. Greten, and F. Korangy, “Innate Lymphoid Cells and Innate-Like T Cells in Cancer—At the Crossroads of Innate and Adaptive Immunity,” Nature Reviews Cancer 23, no. 6 (2023): 351–371.

[234] Y. Gao, F. Souza-Fonseca-Guimaraes, T. Bald, et al., “Tumor Immunoevasion by the Conversion of Effector NK Cells Into Type 1 Innate Lymphoid Cells,” Nature Immunology 18, no. 9 (2017): 1004–1015.

[235] B. Di Luccia, S. Gilfillan, M. Cella, M. Colonna, and S. C. C. Huang, “ILC3s Integrate Glycolysis and Mitochondrial Production of Reactive Oxygen Species to Fulfill Activation Demands,” Journal of Experimental Medicine 216, no. 10 (2019): 2231–2241.

[236] L. Surace, J.-M. Doisne, C. A. Croft, et al., “Dichotomous Metabolic Networks Govern Human ILC2 Proliferation and Function,” Nature Immunology 22, no. 11 (2021): 1367–1374.

[237] H. Chi, M. Pepper, and P. G. Thomas, “Principles and Therapeutic Applications of Adaptive Immunity,” Cell 187, no. 9 (2024): 2052–2078.

[238] M. D. Cooper, “The Early History of B Cells,” Nature Reviews Immunology 15, no. 3 (2015): 191–197.

[239] J. F. A. P. Miller, “The Function of the Thymus and Its Impact on Modern Medicine,” Science 369, no. 6503 (2020): eaba2429.

[240] C. H. Bassing, W. Swat, and F. W. Alt, “The Mechanism and Regulation of Chromosomal V(D)J Recombination,” Cell 109, no. 2 (2002): S45–S55.

[241] T. Mora and A. M. Walczak, “Quantifying Lymphocyte Receptor Diversity,” Systems Immunology (2018), 183–198.

[242] D. A. Michelson and D. Mathis, “Thymic Mimetic Cells: Tolerogenic Masqueraders,” Trends in Immunology 43, no. 10 (2022): 782–791.

[243] G. Gaud, R. Lesourne, and P. E. Love, “Regulatory Mechanisms in T Cell Receptor Signalling,” Nature Reviews Immunology 18, no. 8 (2018): 485–497.

[244] S. M. Kaech, E. J. Wherry, and R. Ahmed, “Effector and Memory T-Cell Differentiation: Implications for Vaccine Development,” Nature Reviews Immunology 2, no. 4 (2002): 251–262.

[245] C. Dong, “Cytokine Regulation and Function in T Cells,” Annual Review of Immunology 39, no. 1 (2021): 51–76.

[246] W. Song and J. Craft, “T Follicular Helper Cell Heterogeneity,” Annual Review of Immunology 42, no. 1 (2024): 127–152.

[247] S. Halle, O. Halle, and R. Förster, “Mechanisms and Dynamics of T Cell-Mediated Cytotoxicity In Vivo,” Trends in Immunology 38, no. 6 (2017): 432–443.

[248] D. Masopust and J. M. Schenkel, “The Integration of T Cell Migration, Differentiation and Function,” Nature Reviews Immunology 13, no. 5 (2013): 309–320.

[249] K. E. de Visser and J. A. Joyce, “The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth,” Cancer Cell 41, no. 3 (2023): 374–403.

[250] A. M. van der Leun, D. S. Thommen, and T. N. Schumacher, “CD8⁺ T Cell States in Human Cancer: Insights From Single-Cell Analysis,” Nature Reviews Cancer 20, no. 4 (2020): 218–232.

[251] D. G. DeNardo and B. Ruffell, “Macrophages as Regulators of Tumour Immunity and Immunotherapy,” Nature Reviews Immunology 19, no. 6 (2019): 369–382.

[252] D. G. DeNardo, J. B. Barreto, P. Andreu, et al., “CD4⁺ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of Macrophages,” Cancer Cell 16, no. 2 (2009): 91–102.

[253] D. Liu, J. Yan, J. Sun, et al., “BCL6 Controls Contact-Dependent Help Delivery During Follicular T-B Cell Interactions,” Immunity 54, no. 10 (2021): 2245–2255.

[254] H. Yoshitomi and H. Ueno, “Shared and Distinct Roles of T Peripheral Helper and T Follicular Helper Cells in Human Diseases,” Cellular & Molecular Immunology 18, no. 3 (2020): 523–527.

[255] Y. Togashi, K. Shitara, and H. Nishikawa, “Regulatory T Cells in Cancer Immunosuppression—Implications for Anticancer Therapy,” Nature Reviews Clinical Oncology 16, no. 6 (2019): 356–371.

[256] B. Silva-Santos, S. Mensurado, and S. B. Coffelt, “γδ T Cells: Pleiotropic Immune Effectors With Therapeutic Potential in Cancer,” Nature Reviews Cancer 19, no. 7 (2019): 392–404.

[257] Q. Yang, J. Na, S. Qin, J. Su, H. Huang, and L. Zhong, “Anticancer Mechanisms and Applications Based on γδ T Cells in Cancer Immunotherapy,” Critical Reviews in Oncology/Hematology 214 (2025): 104814.

[258] J. Liu, M. Wu, Y. Yang, et al., “γδ T Cells and the PD-1/PD-L1 Axis: A Love-Hate Relationship in the Tumor Microenvironment,” Journal of Translational Medicine 22, no. 1 (2024): 553.

[259] G. M. Gerhard, R. Bill, M. Messemaker, A. M. Klein, and M. J. Pittet, “Tumor-Infiltrating Dendritic Cell States Are Conserved Across Solid Human Cancers,” Journal of Experimental Medicine 218, no. 1 (2021): e20200264.

[260] M. Sade-Feldman, K. Yizhak, S. L. Bjorgaard, et al., “Defining T Cell States Associated With Response to Checkpoint Immunotherapy in Melanoma,” Cell 175, no. 4 (2018): 998–1013.e20.

[261] G. Oliveira and C. J. Wu, “Dynamics and Specificities of T Cells in Cancer Immunotherapy,” Nature Reviews Cancer 23, no. 5 (2023): 295–316.

[262] D. S. Thommen and T. N. Schumacher, “T Cell Dysfunction in Cancer,” Cancer Cell 33, no. 4 (2018): 547–562.

[263] A. C. Scott, F. Dündar, P. Zumbo, et al., “TOX Is a Critical Regulator of Tumour-Specific T Cell Differentiation,” Nature 571, no. 7764 (2019): 270–274.

[264] F. Alfei, K. Kanev, M. Hofmann, et al., “TOX Reinforces the Phenotype and Longevity of Exhausted T Cells in Chronic Viral Infection,” Nature 571, no. 7764 (2019): 265–269.

[265] S. M. Kaech and W. Cui, “Transcriptional Control of Effector and Memory CD8⁺ T Cell Differentiation,” Nature Reviews Immunology 12, no. 11 (2012): 749–761.

[266] L. Makowski, M. Chaib, and J. C. Rathmell, “Immunometabolism: From Basic Mechanisms to Translation,” Immunological Reviews 295, no. 1 (2020): 5–14.

[267] R. Eil, S. K. Vodnala, D. Clever, et al., “Ionic Immune Suppression Within the Tumour Microenvironment Limits T Cell Effector Function,” Nature 537, no. 7621 (2016): 539–543.

[268] S. K. Vodnala, R. Eil, R. J. Kishton, et al., “T Cell Stemness and Dysfunction in Tumors Are Triggered by a Common Mechanism,” Science 363, no. 6434 (2019): eaau0135.

[269] Q. Dang, B. Li, B. Jin, et al., “Cancer Immunometabolism: Advent, Challenges, and Perspective,” Molecular Cancer 23, no. 1 (2024): 72.

[270] A. Brand, K. Singer, G. E. Koehl, et al., “LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells,” Cell Metabolism 24, no. 5 (2016): 657–671.

[271] A. Angelin, L. Gil-de-Gómez, S. Dahiya, et al., “Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments,” Cell Metabolism 25, no. 6 (2017): 1282–1293.

[272] M. J. Watson, P. D. A. Vignali, S. J. Mullett, et al., “Metabolic Support of Tumour-Infiltrating Regulatory T Cells by Lactic Acid,” Nature 591, no. 7851 (2021): 645–651.

[273] H. Huang, P. Zhou, J. Wei, et al., “In Vivo CRISPR Screening Reveals Nutrient Signaling Processes Underpinning CD8⁺ T Cell Fate Decisions,” Cell 184, no. 5 (2021): 1245–1261.

[274] S. Varghese, S. Pramanik, L. J. Williams, et al., “The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies,” Molecular Cancer Therapeutics 20, no. 3 (2021): 500–511.

[275] D. H. Munn and A. L. Mellor, “IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance,” Trends in Immunology 37, no. 3 (2016): 193–207.

[276] M. Liu, X. Wang, L. Wang, et al., “Targeting the IDO1 Pathway in Cancer: From Bench to Bedside,” Journal of Hematology & Oncology 11, no. 1 (2018): 100.

[277] P. Briceño, E. Rivas-Yañez, M. V. Rosemblatt, et al., “CD73 Ectonucleotidase Restrains CD8⁺ T Cell Metabolic Fitness and Anti-Tumoral Activity,” Frontiers in Cell and Developmental Biology 9 (2021): 638037.

[278] L. Giuffrida, K. Sek, M. A. Henderson, et al., “CRISPR/Cas9 Mediated Deletion of the Adenosine A2A Receptor Enhances CAR T Cell Efficacy,” Nature Communications 12, no. 1 (2021): 3236.

[279] J. Deng, J. Li, A. Sarde, et al., “Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment,” Cancer Immunology Research 7, no. 7 (2019): 1079–1090.

[280] L. Ziani, S. Buart, S. Chouaib, and J. Thiery, “Hypoxia Increases Melanoma-Associated Fibroblasts Immunosuppressive Potential and Inhibitory Effect on T Cell-Mediated Cytotoxicity,” Oncoimmunology 10, no. 1 (2021): 1950953.

[281] N. E. Scharping, D. B. Rivadeneira, A. V. Menk, et al., “Mitochondrial Stress Induced by Continuous Stimulation Under Hypoxia Rapidly Drives T Cell Exhaustion,” Nature Immunology 22, no. 2 (2021): 205–215.

[282] G. Lenaz, “The Mitochondrial Production of Reactive Oxygen Species: Mechanisms and Implications in Human Pathology,” IUBMB Life 52, no. 3–5 (2008): 159–164.

[283] T. W. Mak, M. Grusdat, G. S. Duncan, et al., “Glutathione Primes T Cell Metabolism for Inflammation,” Immunity 46, no. 4 (2017): 675–689.

[284] R. Wang, C. P. Dillon, L. Z. Shi, et al., “The Transcription Factor Myc Controls Metabolic Reprogramming Upon T Lymphocyte Activation,” Immunity 35, no. 6 (2011): 871–882.

[285] L. A. Sena, S. Li, A. Jairaman, et al., “Mitochondria Are Required for Antigen-Specific T Cell Activation Through Reactive Oxygen Species Signaling,” Immunity 38, no. 2 (2013): 225–236.

[286] C. E. Rockwell, M. Zhang, P. E. Fields, and C. D. Klaassen, “Th2 Skewing by Activation of Nrf2 in CD4⁺ T Cells,” Journal of Immunology 188, no. 4 (2012): 1630–1637.

[287] T. Abimannan, D. Peroumal, J. R. Parida, P. K. Barik, P. Padhan, and S. Devadas, “Oxidative Stress Modulates the Cytokine Response of Differentiated Th17 and Th1 Cells,” Free Radical Biology and Medicine 99 (2016): 352–363.

[288] G. Fu, Q. Xu, Y. Qiu, et al., “Suppression of Th17 Cell Differentiation by Misshapen/NIK-Related Kinase MINK1,” Journal of Experimental Medicine 214, no. 5 (2017): 1453–1469.

[289] X. Yu, Y. Lao, X.-L. Teng, et al., “SENP3 Maintains the Stability and Function of Regulatory T Cells via BACH2 deSUMOylation,” Nature Communications 9, no. 1 (2018): 3157.

[290] D. Unutmaz, H.-R. Kim, A. Lee, et al., “Reactive Oxygen Species Prevent Imiquimod-Induced Psoriatic Dermatitis Through Enhancing Regulatory T Cell Function,” PLoS One 9, no. 3 (2014): e91146.

[291] T. Alissafi, L. Kalafati, M. Lazari, et al., “Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity,” Cell Metabolism 32, no. 4 (2020): 591–604.e7.

[292] C. Procaccini and G. Matarese, “Where Mitochondria Meet Autoimmunity: The Treg Cell Link,” Cell Metabolism 32, no. 4 (2020): 507–509.

[293] H. Kurniawan, D. G. Franchina, L. Guerra, et al., “Glutathione Restricts Serine Metabolism to Preserve Regulatory T Cell Function,” Cell Metabolism 31, no. 5 (2020): 920–936.e7.

[294] L. L. Lu, T. J. Suscovich, S. M. Fortune, and G. Alter, “Beyond Binding: Antibody Effector Functions in Infectious Diseases,” Nature Reviews Immunology 18, no. 1 (2017): 46–61.

[295] J. G. Cyster and C. D. C. Allen, “B Cell Responses: Cell Interaction Dynamics and Decisions,” Cell 177, no. 3 (2019): 524–540.

[296] D. G. Gonzalez, C. M. Cote, J. R. Patel, et al., “Nonredundant Roles of IL-21 and IL-4 in the Phased Initiation of Germinal Center B Cells and Subsequent Self-Renewal Transitions,” Journal of Immunology 201, no. 12 (2018): 3569–3579.

[297] Y. Feng, N. Seija, J. M. Di Noia, and A. Martin, “AID in Antibody Diversification: There and Back Again,” Trends in Immunology 41, no. 7 (2020): 586–600.

[298] T. J. Ripperger and D. Bhattacharya, “Transcriptional and Metabolic Control of Memory B Cells and Plasma Cells,” Annual Review of Immunology 39, no. 1 (2021): 345–368.

[299] T. Inoue and T. Kurosaki, “Memory B Cells,” Nature Reviews Immunology 24, no. 1 (2023): 5–17.

[300] B. A. Heesters, C. E. van der Poel, A. Das, and M. C. Carroll, “Antigen Presentation to B Cells,” Trends in Immunology 37, no. 12 (2016): 844–854.

[301] C. Young and R. Brink, “The Unique Biology of Germinal Center B Cells,” Immunity 54, no. 8 (2021): 1652–1664.

[302] L. Zheng, S. Qin, W. Si, et al., “Pan-Cancer Single-Cell Landscape of Tumor-Infiltrating T Cells,” Science 374, no. 6574 (2021): abe6474.

[303] B. A. Helmink, S. M. Reddy, J. Gao, et al., “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response,” Nature 577, no. 7791 (2020): 549–555.

[304] S. Li, B. Mirlekar, B. M. Johnson, et al., “STING-Induced Regulatory B Cells Compromise NK Function in Cancer Immunity,” Nature 610, no. 7931 (2022): 373–380.

[305] R. Gupta, R. Kumar, C. A. Penn, and N. Wajapeyee, “Immune Evasion in Ovarian Cancer: Implications for Immunotherapy and Emerging Treatments,” Trends in Immunology 46, no. 2 (2025): 166–181.

[306] W. H. Fridman, F. Petitprez, M. Meylan, et al., “B Cells and Cancer: To B or Not to B?,” Journal of Experimental Medicine 218, no. 1 (2021): e20200851.

[307] D. S. Thommen, V. H. Koelzer, P. Herzig, et al., “A Transcriptionally and Functionally Distinct Pd-1⁺ CD8⁺ T Cell Pool With Predictive Potential in Non-Small-Cell Lung Cancer Treated With PD-1 Blockade,” Nature Medicine 24, no. 7 (2018): 994–1004.

[308] Y.-Y. Feng, M. Tang, M. Suzuki, et al., “Essential Role of NADPH Oxidase–Dependent Production of Reactive Oxygen Species in Maintenance of Sustained B Cell Receptor Signaling and B Cell Proliferation,” Journal of Immunology 202, no. 9 (2019): 2546–2557.

[309] D. G. Franchina, H. Kurniawan, M. Grusdat, et al., “Glutathione-Dependent Redox Balance Characterizes the Distinct Metabolic Properties of Follicular and Marginal Zone B Cells,” Nature Communications 13, no. 1 (2022): 1789.

[310] M. W. L. Teng, J. Galon, W.-H. Fridman, and M. J. Smyth, “From Mice to Humans: Developments in Cancer Immunoediting,” Journal of Clinical Investigation 125, no. 9 (2015): 3338–3346.

[311] G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, “Cancer Immunoediting: From Immunosurveillance to Tumor Escape,” Nature Immunology 3, no. 11 (2002): 991–998.

[312] R. D. Schreiber, L. J. Old, and M. J. Smyth, “Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion,” Science 331, no. 6024 (2011): 1565–1570.

[313] M. Sade-Feldman, Y. J. Jiao, J. H. Chen, et al., “Resistance to Checkpoint Blockade Therapy Through Inactivation of Antigen Presentation,” Nature Communications 8, no. 1 (2017): 1136.

[314] N. McGranahan, R. Rosenthal, C. T. Hiley, et al., “Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution,” Cell 171, no. 6 (2017): 1259–1271.e11.

[315] M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, and N. Hacohen, “Molecular and Genetic Properties of Tumors Associated With Local Immune Cytolytic Activity,” Cell 160, no. 1–2 (2015): 48–61.

[316] S. Spranger, R. Bao, and T. F. Gajewski, “Melanoma-Intrinsic β-Catenin Signalling Prevents Anti-Tumour Immunity,” Nature 523, no. 7559 (2015): 231–235.

[317] G. Garrido, B. Schrand, A. Rabasa, et al., “Tumor-Targeted Silencing of the Peptide Transporter TAP Induces Potent Antitumor Immunity,” Nature Communications 10, no. 1 (2019): 3773.

[318] D. M. Pardoll, “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews Cancer 12, no. 4 (2012): 252–264.

[319] W. Zou and L. Chen, “Inhibitory B7-Family Molecules in the Tumour Microenvironment,” Nature Reviews Immunology 8, no. 6 (2008): 467–477.

[320] D. S. Vinay, E. P. Ryan, G. Pawelec, et al., “Immune Evasion in Cancer: Mechanistic Basis and Therapeutic Strategies,” Seminars in Cancer Biology 35 (2015): S185–S198.

[321] J. Nagasaki, T. Ishino, and Y. Togashi, “Mechanisms of Resistance to Immune Checkpoint Inhibitors,” Cancer Science 113, no. 10 (2022): 3303–3312.

[322] L. Ziani, S. Chouaib, and J. Thiery, “Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts,” Frontiers in Immunology 9 (2018): 414.

[323] S. Su, Q. Liu, J. Chen, et al., “A Positive Feedback Loop Between Mesenchymal-Like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis,” Cancer Cell 25, no. 5 (2014): 605–620.

[324] R. Malla, S. Kumari, S. P. Ganji, M. Srilatha, H. R. Nellipudi, and G. P. Nagaraju, “Reactive Oxygen Species of Tumor Microenvironment: Harnessing for Immunogenic Cell Death,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1879, no. 5 (2024): 189154.

[325] K. B. Kennel and F. R. Greten, “Immune Cell-Produced ROS and Their Impact on Tumor Growth and Metastasis,” Redox Biology 42 (2021): 101891.

[326] R. Saleh and E. Elkord, “Acquired Resistance to Cancer Immunotherapy: Role of Tumor-Mediated Immunosuppression,” Seminars in Cancer Biology 65 (2020): 13–27.

[327] X. Zhou, B. An, Y. Lin, Y. Ni, X. Zhao, and X. Liang, “Molecular Mechanisms of ROS-Modulated Cancer Chemoresistance and Therapeutic Strategies,” Biomedicine & Pharmacotherapy 165 (2023): 115036.

[328] Y. Ren, R. Wang, S. Weng, et al., “Multifaceted Role of Redox Pattern in the Tumor Immune Microenvironmen T Regarding Autophagy and Apoptosis,” Molecular Cancer 22, no. 1 (2023): 130.

[329] C.-H. Chang, J. Qiu, D. O'Sullivan, et al., “Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression,” Cell 162, no. 6 (2015): 1229–1241.

[330] C.-H. Chang, J. D. Curtis, L. B. Maggi,., et al., “Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis,” Cell 153, no. 6 (2013): 1239–1251.

[331] A. Kohl, K.-C. Kao, and P.-C. Ho, “Can Tumor Cells Take It All Away?,” Cell Metabolism 33, no. 6 (2021): 1071–1072.

[332] M. A. Badgley, D. M. Kremer, H. C. Maurer, et al., “Cysteine Depletion Induces Pancreatic Tumor Ferroptosis in Mice,” Science 368, no. 6486 (2020): 85–89.

[333] W. Wang, I. Kryczek, L. Dostál, et al., “Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer,” Cell 165, no. 5 (2016): 1092–1105.

[334] C. U. Kidwell, J. R. Casalini, S. Pradeep, et al., “Transferred Mitochondria Accumulate Reactive Oxygen Species, Promoting Proliferation,” eLife 12 (2023): e85494.

[335] S. Xu, O. Chaudhary, P. Rodríguez-Morales, et al., “Uptake of Oxidized Lipids by the Scavenger Receptor CD36 Promotes Lipid Peroxidation and Dysfunction in CD8⁺ T Cells in Tumors,” Immunity 54, no. 7 (2021): 1561–1577.e7.

[336] K. C. Hicks, Y. Y. Tyurina, V. E. Kagan, and D. I. Gabrilovich, “Myeloid Cell-Derived Oxidized Lipids and Regulation of the Tumor Micro Environment,” Cancer Research 82, no. 2 (2022): 187–194.

[337] M. Molina-Arcas and J. Downward, “Exploiting the Therapeutic Implications of KRAS Inhibition on Tumor Im Munity,” Cancer Cell 42, no. 3 (2024): 338–357.

[338] H. Branco, C. P. R. Xavier, C. Riganti, and M. H. Vasconcelos, “Hypoxia as a Critical Player in Extracellular Vesicles-Mediated Intercellular Communication Between Tumor Cells and Their Surrounding Microenvironment,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1880, no. 1 (2025): 189244.

[339] S. Nagaraj, K. Gupta, V. Pisarev, et al., “Altered Recognition of Antigen Is a Mechanism of CD8⁺ T Cell Tolerance in Cancer,” Nature Medicine 13, no. 7 (2007): 828–835.

[340] B. Molon, S. Ugel, F. Del Pozzo, et al., “Chemokine Nitration Prevents Intratumoral Infiltration of Antigen-Specific T Cells,” Journal of Experimental Medicine 208, no. 10 (2011): 1949–1962.

[341] E. N. Tcyganov, E. Sanseviero, D. Marvel, et al., “Peroxynitrite in the Tumor Microenvironment Changes the Profile of Antigens Allowing Escape From Cancer Immunotherapy,” Cancer Cell 40, no. 10 (2022): 1173–1189.e6.

[342] A. Taylor, J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis, “Mechanisms of Immune Suppression by interleukin-10 and Transforming Growth Factor-β: The Role of T Regulatory Cells,” Immunology 117, no. 4 (2006): 433–442.

[343] V. G. Cooke, V. S. LeBleu, D. Keskin, et al., “Pericyte Depletion Results in Hypoxia-Associated Epithelial-To-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway,” Cancer Cell 21, no. 1 (2012): 66–81.

[344] C. Branco-Price, N. Zhang, M. Schnelle, et al., “Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success,” Cancer Cell 21, no. 1 (2012): 52–65.

[345] S. Gu and X.-H. Feng, “TGF-β Signaling in Cancer,” Acta Biochimica et Biophysica Sinica 50, no. 10 (2018): 941–949.

[346] H. Zhang, Z. Yang, W. Yuan, et al., “Sustained AhR Activity Programs Memory Fate of Early Effector CD8⁺ T Cells,” Proceedings of the National Academy of Sciences 121, no. 11 (2024): e2317658121.

[347] B. M. Matata and M. Galiñanes, “Peroxynitrite Is an Essential Component of Cytokines Production Mechanism in Human Monocytes Through Modulation of Nuclear Factor-κB DNA Binding Activity,” Journal of Biological Chemistry 277, no. 3 (2002): 2330–2335.

[348] R. Yang, C. Qu, Y. Zhou, et al., “Hydrogen Sulfide Promotes Tet1- and Tet2-Mediated Foxp3 Demethylation to Drive Regulatory T Cell Differentiation and Maintain Immune Homeostasis,” Immunity 43, no. 2 (2015): 251–263.

[349] J. Liu, M. Wu, Y. Yang, et al., “BTN3A1 Expressed in Cervical Cancer Cells Promotes Vγ9Vδ2 T Cells Exhaustion Through Upregulating Transcription Factors NR4A2/3 Downstream of TCR Signaling,” Cell Communication and Signaling 22, no. 1 (2024): 459.

[350] L. Wang, J. Ge, H. Han, et al., “Crosstalk Between the Nervous System and Tumor Microenvironment: Functional Aspects and Potential Therapeutic Strategies,” Cancer Letters 594 (2024): 216986.

[351] K. Newton, A. Strasser, N. Kayagaki, and V. M. Dixit, “Cell Death,” Cell 187, no. 2 (2024): 235–256.

[352] X. An, W. Yu, J. Liu, D. Tang, L. Yang, and X. Chen, “Oxidative Cell Death in Cancer: Mechanisms and Therapeutic Opportunities,” Cell Death & Disease 15, no. 8 (2024): 556.

[353] K. Hänggi and B. Ruffell, “Cell Death, Therapeutics, and the Immune Response in Cancer,” Trends in Cancer 9, no. 5 (2023): 381–396.

[354] H. K. C. Co, C.-C. Wu, Y.-C. Lee, and S. Chen, “Emergence of Large-Scale Cell Death Through Ferroptotic Trigger Waves,” Nature 631, no. 8021 (2024): 654–662.

[355] H. Zheng, J. Liu, Q. Cheng, et al., “Targeted Activation of Ferroptosis in Colorectal Cancer via LGR4 Targeting Overcomes Acquired Drug Resistance,” Nature Cancer 5, no. 4 (2024): 572–589.

[356] Y. Wang, M. Hu, J. Cao, et al., “ACSL4 and Polyunsaturated Lipids Support Metastatic Extravasation and Colonization,” Cell 188, no. 2 (2025): 412–429.

[357] B. Qiu, F. Zandkarimi, C. T. Bezjian, et al., “Phospholipids With Two Polyunsaturated Fatty Acyl Tails Promote Ferroptosis,” Cell 187, no. 5 (2024): 1177–1190.e18.

[358] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht, et al., “Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death,” Cell 149, no. 5 (2012): 1060–1072.

[359] B. Chu, N. Kon, D. Chen, et al., “ALOX12 Is Required for p53-Mediated Tumour Suppression Through a Distinct Ferroptosis Pathway,” Nature Cell Biology 21, no. 5 (2019): 579–591.

[360] G. Lei, Y. Zhang, T. Hong, et al., “Ferroptosis as a Mechanism to Mediate p53 Function in Tumor Radiosensitivity,” Oncogene 40, no. 20 (2021): 3533–3547.

[361] Y. Zhang, J. Shi, X. Liu, et al., “BAP1 Links Metabolic Regulation of Ferroptosis to Tumour Suppression,” Nature Cell Biology 20, no. 10 (2018): 1181–1192.

[362] S. Lei, C. Chen, F. Han, et al., “AMER1 Deficiency Promotes the Distant Metastasis of Colorectal Cancer by Inhibiting SLC7A11- and FTL-Mediated Ferroptosis,” Cell Reports 42, no. 9 (2023): 113110.

[363] B. Hassannia, P. Vandenabeele, and T. Vanden Berghe, “Targeting Ferroptosis to Iron Out Cancer,” Cancer Cell 35, no. 6 (2019): 830–849.

[364] V. S. Viswanathan, M. J. Ryan, H. D. Dhruv, et al., “Dependency of a Therapy-Resistant State of Cancer Cells on a Lipid Peroxidase Pathway,” Nature 547, no. 7664 (2017): 453–457.

[365] K. Bersuker, J. M. Hendricks, Z. Li, et al., “The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis,” Nature 575, no. 7784 (2019): 688–692.

[366] S. Doll, F. P. Freitas, R. Shah, et al., “FSP1 Is a Glutathione-Independent Ferroptosis Suppressor,” Nature 575, no. 7784 (2019): 693–698.

[367] W. Wang, M. Green, J. E. Choi, et al., “CD8⁺ T Cells Regulate Tumour Ferroptosis During Cancer Immunotherapy,” Nature 569, no. 7755 (2019): 270–274.

[368] P. Liao, W. Wang, W. Wang, et al., “CD8⁺ T Cells and Fatty Acids Orchestrate Tumor Ferroptosis and Immunity via ACSL4,” Cancer Cell 40, no. 4 (2022): 365–378.e6.

[369] P. P. Yee, Y. Wei, S.-Y. Kim, et al., “Neutrophil-Induced Ferroptosis Promotes Tumor Necrosis in Glioblastoma Progression,” Nature Communications 11, no. 1 (2020): 5424.

[370] J. Yi, J. Zhu, J. Wu, C. B. Thompson, and X. Jiang, “Oncogenic Activation of PI3K-AKT-mTOR Signaling Suppresses Ferroptosis via SREBP-Mediated Lipogenesis,” Proceedings of the National Academy of Sciences 117, no. 49 (2020): 31189–31197.

[371] M. Sabatier, R. Birsen, L. Lauture, et al., “C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis inFLT3-Mutant Leukemia,” Cancer Discovery 13, no. 7 (2023): 1720–1747.

[372] J. Zhang, Y. Wei, Y. Yue, et al., “RIPK4 Promotes Oxidative Stress and Ferroptotic Death Through the Down Regulation of ACSM1,” Proceedings of the National Academy of Sciences 121, no. 40 (2024): e2410628121.

[373] W. S. Yang, R. SriRamaratnam, M. E. Welsch, et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4,” Cell 156, no. 1–2 (2014): 317–331.

[374] V. A. N. Kraft, C. T. Bezjian, S. Pfeiffer, et al., “GTP Cyclohydrolase 1/Tetrahydrobiopterin Counteract Ferroptosis Through Lipid Remodeling,” ACS Central Science 6, no. 1 (2019): 41–53.

[375] X. Jiang, B. R. Stockwell, and M. Conrad, “Ferroptosis: Mechanisms, Biology and Role in Disease,” Nature Reviews Molecular Cell Biology 22, no. 4 (2021): 266–282.

[376] L. Zhou, G. Lian, T. Zhou, et al., “Palmitoylation of GPX4 via the Targetable ZDHHC8 Determines Ferroptosis Sensitivity and Antitumor Immunity,” Nature Cancer 6, no. 5 (2025): 768–785.

[377] G. Lei, L. Zhuang, and B. Gan, “The Roles of Ferroptosis in Cancer: Tumor Suppression, Tumor Microenvi Ronment, and Therapeutic Interventions,” Cancer Cell 42, no. 4 (2024): 513–534.

[378] M. Kciuk, A. Gielecińska, Ż. Kałuzińska-Kołat, E. B. Yahya, and R. Kontek, “Ferroptosis and Cuproptosis: Metal-Dependent Cell Death Pathways Activ Ated in Response to Classical Chemotherapy—Significance for Cancer Treatment?,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1879, no. 4 (2024): 189124.

[379] C. Fei, X. Zhen, Z. Shiqiang, and P. Jun, “Frontier Knowledge and Future Directions of Programmed Cell Death in Clear Cell Renal Cell Carcinoma,” Cell Death Discovery 10, no. 1 (2024): 113.

[380] R. Kim, D. Taylor, R. H. Vonderheide, and D. I. Gabrilovich, “Ferroptosis of Immune Cells in the Tumor Microenvironment,” Trends in Pharmacological Sciences 44, no. 8 (2023): 542–552.

[381] X. Zhai, Y. Lin, L. Zhu, et al., “Ferroptosis in Cancer Immunity and Immunotherapy: Multifaceted Interplay and Clinical Implications,” Cytokine & Growth Factor Reviews 75 (2024): 101–109.

[382] X. Liu, S. Xia, Z. Zhang, H. Wu, and J. Lieberman, “Channelling Inflammation: Gasdermins in Physiology and Disease,” Nature Reviews Drug Discovery 20, no. 5 (2021): 384–405.

[383] J. Shi, W. Gao, and F. Shao, “Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death,” Trends in Biochemical Sciences 42, no. 4 (2017): 245–254.

[384] S. Kesavardhana, R. K. S. Malireddi, and T.-D. Kanneganti, “Caspases in Cell Death, Inflammation, and Pyroptosis,” Annual Review of Immunology 38, no. 1 (2020): 567–595.

[385] K. V. Swanson, M. Deng, and J. P. Y. Ting, “The NLRP3 Inflammasome: Molecular Activation and Regulation to Therapeutics,” Nature Reviews Immunology 19, no. 8 (2019): 477–489.

[386] J. Shi, Y. Zhao, K. Wang, et al., “Cleavage of GSDMD by Inflammatory Caspases Determines Pyroptotic Cell Death,” Nature 526, no. 7575 (2015): 660–665.

[387] N. Kayagaki, S. Warming, M. Lamkanfi, et al., “Non-Canonical Inflammasome Activation Targets Caspase-11,” Nature 479, no. 7371 (2011): 117–121.

[388] L. K. Billingham, J. S. Stoolman, K. Vasan, et al., “Mitochondrial Electron Transport Chain Is Necessary for NLRP3 Inflammasome Activation,” Nature Immunology 23, no. 5 (2022): 692–704.

[389] Z. Zhong, S. Liang, E. Sanchez-Lopez, et al., “New Mitochondrial DNA Synthesis Enables NLRP3 Inflammasome Activation,” Nature 560, no. 7717 (2018): 198–203.

[390] G. Du, L. B. Healy, L. David, et al., “ROS-Dependent S-Palmitoylation Activates Cleaved and Intact Gasdermin D,” Nature 630, no. 8016 (2024): 437–446.

[391] T. Ma, X. Tian, B. Zhang, et al., “Low-Dose Metformin Targets the Lysosomal AMPK Pathway Through PEN2,” Nature 603, no. 7899 (2022): 159–165.

[392] H. Xian, Y. Liu, A. Rundberg Nilsson, et al., “Metformin Inhibition of Mitochondrial ATP and DNA Synthesis Abrogates NLRP3 Inflammasome Activation and Pulmonary Inflammation,” Immunity 54, no. 7 (2021): 1463–1477.e11.

[393] R. Turpin, R. Liu, P. M. Munne, et al., “Respiratory Complex I Regulates Dendritic Cell Maturation in Explant Model of Human Tumor Immune Microenvironment,” Journal for Immunotherapy of Cancer 12, no. 4 (2024): e008053.

[394] L. Qiao, G. Zhu, T. Jiang, et al., “Self-Destructive Copper Carriers Induce Pyroptosis and Cuproptosis for Efficient Tumor Immunotherapy Against Dormant and Recurrent Tumors,” Advanced Materials 36, no. 8 (2023): e2308241.

[395] L. Lu, Y. Zhang, X. Tan, et al., “Emerging Mechanisms of Pyroptosis and Its Therapeutic Strategy in Cancer,” Cell Death Discovery 8, no. 1 (2022): 338.

[396] Z. He, D. Feng, C. Zhang, et al., “Recent Strategies for Evoking Immunogenic Pyroptosis in Antitumor Immunotherapy,” Journal of Controlled Release 366 (2024): 375–394.

[397] A. Qiu, J. Lin, H. Hu, et al., “Organelles and Cancer Cell Pyroptosis: Overview and Perspectives,” Cell Death & Disease 17, no. 1 (2025): 142.

[398] B. Zhou, J. Zhang, X. Liu, et al., “Tom20 Senses Iron-Activated ROS Signaling to Promote Melanoma Cell Pyroptosis,” Cell Research 28, no. 12 (2018): 1171–1185.

[399] C. G. Weindel, E. L. Martinez, X. Zhao, et al., “Mitochondrial ROS Promotes Susceptibility to Infection via Gasdermin D-Mediated Necroptosis,” Cell 185, no. 17 (2022): 3214–3231.e23.

[400] Y. Wang, W. Gao, X. Shi, et al., “Chemotherapy Drugs Induce Pyroptosis Through Caspase-3 Cleavage of a Gasdermin,” Nature 547, no. 7661 (2017): 99–103.

[401] Z. Zhang, Y. Zhang, S. Xia, et al., “Gasdermin E Suppresses Tumour Growth by Activating Anti-Tumour Immunity,” Nature 579, no. 7799 (2020): 415–420.

[402] S. T. Diepstraten, M. A. Anderson, P. E. Czabotar, G. Lessene, A. Strasser, and G. L. Kelly, “The Manipulation of Apoptosis for Cancer Therapy Using BH3-Mimetic Drugs,” Nature Reviews Cancer 22, no. 1 (2021): 45–64.

[403] K. McArthur, L. W. Whitehead, J. M. Heddleston, et al., “Bak/Bax Macropores Facilitate Mitochondrial Herniation and mtDNA Efflux During Apoptosis,” Science 359, no. 6378 (2018): eaao6047.

[404] B. A. Carneiro and W. S. El-Deiry, “Targeting Apoptosis in Cancer Therapy,” Nature Reviews Clinical Oncology 17, no. 7 (2020): 395–417.

[405] A. Barbouti, C. Amorgianiotis, E. Kolettas, P. Kanavaros, and D. Galaris, “Hydrogen Peroxide Inhibits Caspase-Dependent Apoptosis by Inactivating Procaspase-9 in an Iron-Dependent Manner,” Free Radical Biology and Medicine 43, no. 10 (2007): 1377–1387.

[406] S. J. F. Chong, S. Marchi, G. Petroni, G. Kroemer, L. Galluzzi, and S. Pervaiz, “Noncanonical Cell Fate Regulation by Bcl-2 Proteins,” Trends in Cell Biology 30, no. 7 (2020): 537–555.

[407] P. E. Czabotar and A. J. Garcia-Saez, “Mechanisms of BCL-2 Family Proteins in Mitochondrial Apoptosis,” Nature Reviews Molecular Cell Biology 24, no. 10 (2023): 732–748.

[408] C. Oh, T. Nakamura, X. Zhang, and S. A. Lipton, “Redox Regulation, Protein S-Nitrosylation, and Synapse Loss in Alzheimer's and Related Dementias,” Neuron 112, no. 23 (2024): 3823–3850.

[409] M. A. Carpio, R. E. Means, A. L. Brill, A. Sainz, B. E. Ehrlich, and S. G. Katz, “BOK Controls Apoptosis by Ca²⁺ Transfer Through ER-Mitochondrial Contact Sites,” Cell Reports 34, no. 10 (2021): 108827.

[410] R. He, Y. Liu, W. Fu, et al., “Mechanisms and Cross-Talk of Regulated Cell Death and Their Epigenetic Modifications in Tumor Progression,” Molecular Cancer 23, no. 1 (2024): 267.

[411] M. Wang, S. Deng, Y. Cao, et al., “Injectable Versatile Liquid-Solid Transformation Implants Alliance Check Point Blockade for Magnetothermal Dynamic-Immunotherapy,” Materials Today Bio 16 (2022): 100442.

[412] C. M. Alicea Pauneto, B. P. Riesenberg, E. J. Gandy, et al., “Intra-Tumoral Hypoxia Promotes CD8⁺T Cell Dysfunction via Chronic Activation of Integrated Stress Response Transcription Factor ATF4,” Immunity 58, no. 10 (2025): 2489–2504.e8.

[413] J. Yan, P. Wan, S. Choksi, and Z. G. Liu, “Necroptosis and Tumor Progression,” Trends in Cancer 8, no. 1 (2022): 21–27.

[414] R. Tang, J. Xu, B. Zhang, et al., “Ferroptosis, Necroptosis, and Pyroptosis in Anticancer Immunity,” Journal of Hematology & Oncology 13, no. 1 (2020): 110.

[415] Y. Wang, Y. Wang, J. Pan, L. Gan, and J. Xue, “Ferroptosis, Necroptosis, and Pyroptosis in Cancer: Crucial Cell Death Types in Radiotherapy and Post-Radiotherapy Immune Activation,” Radiotherapy and Oncology 184 (2023): 109689.

[416] M. Seehawer, F. Heinzmann, L. D'Artista, et al., “Necroptosis Microenvironment Directs Lineage Commitment in Liver Cancer,” Nature 562, no. 7725 (2018): 69–75.

[417] T. Zhang, C. Yin, A. Fedorov, et al., “ADAR1 Masks the Cancer Immunotherapeutic Promise of ZBP1-Driven Necroptosis,” Nature 606, no. 7914 (2022): 594–602.

[418] P. Kang, J. Chen, W. Zhang, et al., “Oxeiptosis: A Novel Pathway of Melanocytes Death in Response to Oxidative Stress in Vitiligo,” Cell Death Discovery 8, no. 1 (2022): 70.

[419] C. Holze, C. Michaudel, C. Mackowiak, et al., “Oxeiptosis, a ROS-Induced Caspase-Independent Apoptosis-Like Cell-Death Pathway,” Nature Immunology 19, no. 2 (2017): 130–140.

[420] S. Pallichankandy, F. Thayyullathil, A. R. Cheratta, et al., “Targeting Oxeiptosis-Mediated Tumor Suppression: A Novel Approach to Treat Colorectal Cancers by Sanguinarine,” Cell Death Discovery 9, no. 1 (2023): 94.

[421] B. G. Yipp and P. Kubes, “NETosis: How Vital Is It?,” Blood 122, no. 16 (2013): 2784–2794.

[422] V. Papayannopoulos, “Neutrophil Extracellular Traps in Immunity and Disease,” Nature Reviews Immunology 18, no. 2 (2017): 134–147.

[423] C. Lood, L. P. Blanco, M. M. Purmalek, et al., “Neutrophil Extracellular Traps Enriched in Oxidized Mitochondrial DNA Are Interferogenic and Contribute to Lupus-Like Disease,” Nature Medicine 22, no. 2 (2016): 146–153.

[424] M. H. Shahzad, R. F. Rayes, J. Cools-Lartigue, and J. D. Spicer, “Neutrophil Extracellular Traps in Cancer,” Nature Reviews Cancer 26, no. 2 (2026): 104–117.

[425] J. Cools-Lartigue, J. Spicer, B. McDonald, et al., “Neutrophil Extracellular Traps Sequester Circulating Tumor Cells and Promote Metastasis,” Journal of Clinical Investigation 123, no. 8 (2013): 3446–3458.

[426] F. Wen, A. Shen, A. Choi, E. W. Gerner, and J. Shi, “Extracellular DNA in Pancreatic Cancer Promotes Cell Invasion and Metastasis,” Cancer Research 73, no. 14 (2013): 4256–4266.

[427] Y. Wang, K. Yang, J. Li, C. Wang, P. Li, and L. Du, “Neutrophil Extracellular Traps in Cancer: From Mechanisms to Treatments,” Clinical and Translational Medicine 15, no. 6 (2025): e70368.

[428] E.-H. Choi and S.-J. Park, “TXNIP: A Key Protein in the Cellular Stress Response Pathway and a Potential Therapeutic Target,” Experimental & Molecular Medicine 55, no. 7 (2023): 1348–1356.

[429] G. van Loo and M. J. M. Bertrand, “Death by TNF: A Road to Inflammation,” Nature Reviews Immunology 23, no. 5 (2022): 289–303.

[430] S. Yang, C. Hu, X. Chen, et al., “Crosstalk Between Metabolism and Cell Death in Tumorigenesis,” Molecular Cancer 23, no. 1 (2024): 71.

[431] S.-H. Hao, X.-D. Ma, L. Xu, et al., “Dual Specific Phosphatase 4 Suppresses Ferroptosis and Enhances Sorafenib Resistance in Hepatocellular Carcinoma,” Drug Resistance Updates 73 (2024): 101052.

[432] D. Ren, N. F. Villeneuve, T. Jiang, et al., “Brusatol Enhances the Efficacy of Chemotherapy by Inhibiting the Nrf2-Mediated Defense Mechanism,” Proceedings of the National Academy of Sciences 108, no. 4 (2011): 1433–1438.

[433] K. Tsuchida, T. Tsujita, M. Hayashi, et al., “Halofuginone Enhances the Chemo-Sensitivity of Cancer Cells by Suppressing NRF2 Accumulation,” Free Radical Biology and Medicine 103 (2017): 236–247.

[434] C. Sun, B. Han, Y. Zhai, et al., “Dihydrotanshinone I Inhibits Ovarian Tumor Growth by Activating Oxidative Stress Through Keap1-Mediated Nrf2 Ubiquitination Degradation,” Free Radical Biology and Medicine 180 (2022): 220–235.

[435] M. A. Cucci, M. Grattarola, C. Dianzani, et al., “Ailanthone Increases Oxidative Stress in CDDP-Resistant Ovarian and Bladder Cancer Cells by Inhibiting of Nrf2 and YAP Expression Through a Post-Translational Mechanism,” Free Radical Biology and Medicine 150 (2020): 125–135.

[436] X. Tang, H. Wang, L. Fan, et al., “Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/ARE Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs,” Free Radical Biology and Medicine 50, no. 11 (2011): 1599–1609.

[437] Y. Liu, Y. Wang, J. Wang, et al., “Fangchinoline Suppresses Hepatocellular Carcinoma by Regulating ROS Accumulation via the TRIM7/Nrf2 Signaling Pathway,” Phytomedicine 135 (2024): 156143.

[438] X. Xu, Z. Li, J. Zhao, et al., “Catalase-Conjugated Rose Bengal Biological Nanoparticles With Mitochondrial Selectivity Toward Photodynamic Therapy,” CCS Chemistry 5, no. 12 (2023): 2877–2887.

[439] X.-N. Wu, J. Li, Q. He, et al., “Targeting the PHF8/YY1 Axis Suppresses Cancer Cell Growth Through Modulation of ROS,” Proceedings of the National Academy of Sciences 121, no. 2 (2024): e2219352120.

[440] L. Zhu, Y. Zhao, T. Liu, et al., “Inhibition of NADPH Oxidase-ROS Signal Using Hyaluronic Acid Nanoparticles for Overcoming Radioresistance in Cancer Therapy,” ACS Nano 16, no. 11 (2022): 18708–18728.

[441] J. Reis, C. Gorgulla, M. Massari, et al., “Targeting ROS Production Through Inhibition of NADPH Oxidases,” Nature Chemical Biology 19, no. 12 (2023): 1540–1550.

[442] Z. Huang, Q. Su, W. Li, H. Ren, H. Huang, and A. Wang, “Suppressed Mitochondrial Respiration via NOX5-Mediated Redox Imbalance Contributes to the Antitumor Activity of Anlotinib in Oral Squamous Cell Carcinoma,” Journal of Genetics and Genomics 48, no. 7 (2021): 582–594.

[443] S. Sun, X. Huang, N. Yang, et al., “Fluorinated Titanium Oxide (TiO₂–xFx) Nanospindles as Ultrasound-Triggered Pyroptosis Inducers to Boost Sonodynamic Immunotherapy,” ACS Nano 10 (2024): 102.

[444] Y. Liu, Y. Wang, S. Song, and H. Zhang, “Cascade-Responsive Nanobomb With Domino Effect for Anti-Tumor Synergistic Therapies,” National Science Review 9, no. 3 (2022): nwab139.

[445] J. Zou, C. Jiang, Q. Hu, et al., “Tumor Microenvironment-Responsive Engineered Hybrid Nanomedicine for Photodynamic-Immunotherapy via Multi-Pronged Amplification of Reactive Oxygen Species,” Nature Communications 16, no. 1 (2025): 424.

[446] L. He, L. Wang, X. Yu, et al., “Full-Course NIR-II Imaging-Navigated Fractionated Photodynamic Therapy of Bladder Tumours With X-Ray-Activated Nanotransducers,” Nature Communications 15, no. 1 (2024): 8240.

[447] D. Trachootham, Y. Zhou, H. Zhang, et al., “Selective Killing of Oncogenically Transformed Cells Through a ROS-Mediated Mechanism by β-Phenylethyl Isothiocyanate,” Cancer Cell 10, no. 3 (2006): 241–252.

[448] A. P. Lawson, M. J. C. Long, R. T. Coffey, et al., “Naturally Occurring Isothiocyanates Exert Anticancer Effects by Inhibiting Deubiquitinating Enzymes,” Cancer Research 75, no. 23 (2015): 5130–5142.

[449] V. J. N. Bykov, S. E. Eriksson, J. Bianchi, and K. G. Wiman, “Targeting Mutant p53 for Efficient Cancer Therapy,” Nature Reviews Cancer 18, no. 2 (2018): 89–102.

[450] M. J. Hangauer, V. S. Viswanathan, M. J. Ryan, et al., “Drug-Tolerant Persister Cancer Cells Are Vulnerable to GPX4 Inhibition,” Nature 551, no. 7679 (2017): 247–250.

[451] W. Fiskus, N. Saba, M. Shen, et al., “Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity Against Chronic Lymphocytic Leukemia,” Cancer Research 74, no. 9 (2014): 2520–2532.

[452] Z. Liu, J. Zhang, H. Liu, et al., “BSA-AIE Nanoparticles With Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma,” Advanced Materials 35, no. 7 (2023): e2208692.

[453] Y. Gao, Z. Song, L. Jia, et al., “Self-Amplified ROS Production From Fatty Acid Oxidation Enhanced Tumor Immunotherapy by Atorvastatin/PD-L1 siRNA Lipopeptide Nanoplexes,” Biomaterials 291 (2022): 121902.

[454] J. D. Schoenfeld, Z. A. Sibenaller, K. A. Mapuskar, et al., “O₂⋅− and H₂O₂-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate,” Cancer Cell 31, no. 4 (2017): 487–500.

[455] B. Gan, “How Erastin Assassinates Cells by Ferroptosis Revealed,” Protein & Cell 14, no. 2 (2022): 84–86.

[456] J. Tschopp and K. Schroder, “NLRP3 Inflammasome Activation: The Convergence of Multiple Signalling Pathways on ROS Production?,” Nature Reviews Immunology 10, no. 3 (2010): 210–215.

[457] D. Chen, G. Zhang, R. Li, et al., “Biodegradable, Hydrogen Peroxide, and Glutathione Dual Responsive Nanoparticles for Potential Programmable Paclitaxel Release,” Journal of the American Chemical Society 140, no. 24 (2018): 7373–7376.

[458] X. Fan, Y. Dai, C. Mo, et al., “TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism,” Advancement of Science 12, no. 8 (2024): e2413674.

[459] Y. Chen, J. Shi, X. Wang, et al., “An Antioxidant Feedforward Cycle Coordinated by Linker Histone Variant H1. 2 and NRF2 That Drives Nonsmall Cell Lung Cancer Progression,” Proceedings of the National Academy of Sciences 120, no. 39 (2023): e2306288120.

[460] H. Panda, M. Suzuki, M. Naito, et al., “Halofuginone Micelle Nanoparticles Eradicate Nrf2-Activated Lung Adenocarcinoma Without Systemic Toxicity,” Free Radical Biology and Medicine 187 (2022): 92–104.

[461] C. Sun, F. Xie, H. Zhang, et al., “Paclitaxel/Luteolin Coloaded Dual-Functional Liposomes for Esophageal Cancer Therapy,” Advanced Science 12, no. 20 (2025): e2411930.

[462] H. Peng, F. Yao, J. Zhao, et al., “Unraveling Mitochondria-Targeting Reactive Oxygen Species Modulation and Their Implementations in Cancer Therapy by Nanomaterials,” Exploration 3, no. 2 (2023): 20220115.

[463] D. Bezwada, L. Perelli, N. P. Lesner, et al., “Mitochondrial Complex I Promotes Kidney Cancer Metastasis,” Nature 633, no. 8031 (2024): 923–931.

[464] S. Han, M. Lee, Y. Shin, et al., “Mitochondrial Integrated Stress Response Controls Lung Epithelial Cell Fate,” Nature 620, no. 7975 (2023): 890–897.

[465] J. Xie, Y. Wang, W. Choi, et al., “Overcoming Barriers in Photodynamic Therapy Harnessing Nano-Formulation Strategies,” Chemical Society Reviews 50, no. 16 (2021): 9152–9201.

[466] M. Yang, X. Wang, M. Peng, et al., “Nanomaterials Enhanced Sonodynamic Therapy for Multiple Tumor Treatment,” Nano-Micro Letters 17, no. 1 (2025): 157.

[467] S. Li, Y. Zhao, W. Ma, et al., “A Multivalent Polyphenol–Metal-Nanoplatform for Cascade Amplified Chemo-Chemodynamic Therapy,” Acta Biomaterialia 173 (2024): 389–402.

[468] Q. Guo, Y. Tang, S. Wang, and X. Xia, “Applications and Enhancement Strategies of ROS-Based Non-Invasive Therapies in Cancer Treatment,” Redox Biology 80 (2025): 103515.

[469] M. K. Sundaram, P. R, S. Haque, et al., “Dietary Isothiocyanates Inhibit Cancer Progression by Modulation of Epigenome,” Seminars in Cancer Biology 83 (2022): 353–376.

[470] Y. Hu, W. Lu, G. Chen, et al., “Overcoming Resistance to Histone Deacetylase Inhibitors in Human Leukemia With the Redox Modulating Compound β-Phenylethyl Isothiocyanate,” Blood 116, no. 15 (2010): 2732–2741.

[471] H. Zhang, D. Trachootham, W. Lu, et al., “Effective Killing of Gleevec-Resistant CML Cells With T315I Mutation by a Natural Compound PEITC Through Redox-Mediated Mechanism,” Leukemia 22, no. 6 (2008): 1191–1199.

[472] E. Mishima, T. Nakamura, S. Doll, et al., “Recommendations for Robust and Reproducible Research on Ferroptosis,” Nature Reviews Molecular Cell Biology 26, no. 8 (2025): 615–630.

[473] Y. Xie, R. Kang, D. J. Klionsky, and D. Tang, “GPX4 in Cell Death, Autophagy, and Disease,” Autophagy 19, no. 10 (2023): 2621–2638.

[474] J. Liu, D. Tang, and R. Kang, “Targeting GPX4 in Ferroptosis and Cancer: Chemical Strategies and Challenges,” Trends in Pharmacological Sciences 45, no. 8 (2024): 666–670.

[475] M. Yang, J. Liu, J. Li, et al., “The Rheumatoid Arthritis Drug Auranofin Exerts Potent Anti-Lymphoma Effect by Stimulating TXNRD-Mediated ROS Generation and Inhibition of Energy Metabolism,” Redox Biology 75 (2024): 103245.

[476] K. A. Gelderman, M. Hultqvist, J. Holmberg, P. Olofsson, and R. Holmdahl, “T Cell Surface Redox Levels Determine T Cell Reactivity and Arthritis Susceptibility,” Proceedings of the National Academy of Sciences 103, no. 34 (2006): 12831–12836.

[477] C. Glorieux, X. Xia, Y.-Q. He, et al., “Regulation of PD-L1 Expression in K-Ras-Driven Cancers Through ROS-Mediated FGFR1 Signaling,” Redox Biology 38 (2021): 101780.

[478] Z. Zhao, S. Dong, Y. Liu, et al., “Tumor Microenvironment-Activable Manganese-Boosted Catalytic Immunotherapy Combined With PD-1 Checkpoint Blockade,” ACS Nano 16, no. 12 (2022): 20400–20418.

[479] Y. Zhu, Y. Li, X. Li, et al., “Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma,” Advanced Healthcare Materials 13, no. 32 (2024): e2402973.

[480] C. J. Hanley, M. Mellone, K. Ford, et al., “Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4,” JNCI: Journal of the National Cancer Institute 110, no. 1 (2018): 109–120.

[481] K. Ford, C. J. Hanley, M. Mellone, et al., “NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-Cell Exclusion From Tumors,” Cancer Research 80, no. 9 (2020): 1846–1860.

[482] Y. Ye, A. Chen, L. Li, et al., “Repression of the Antiporter SLC7A11/Glutathione/Glutathione Peroxidase 4 Axis Drives Ferroptosis of Vascular Smooth Muscle Cells to Facilitate Vascular Calcification,” Kidney International 102, no. 6 (2022): 1259–1275.

[483] N. Yagoda, M. von Rechenberg, E. Zaganjor, et al., “RAS–RAF–MEK-Dependent Oxidative Cell Death Involving Voltage-Dependent Anion Channels,” Nature 447, no. 7146 (2007): 865–869.

[484] D. N. DeHart, D. Fang, K. Heslop, L. Li, J. J. Lemasters, and E. N. Maldonado, “Opening of Voltage Dependent Anion Channels Promotes Reactive Oxygen Species Generation, Mitochondrial Dysfunction and Cell Death in Cancer Cells,” Biochemical Pharmacology 148 (2018): 155–162.

[485] W. Cao, X. Zhang, Y. Feng, et al., “Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic With Programmed Cell Death-Ligand 1 Downregulation,” ACS Nano 18, no. 26 (2024): 17267–17281.

[486] T.-X. Wang, J.-Y. Liang, C. Zhang, Y. Xiong, K. L. Guan, and H. X. Yuan, “The Oncometabolite 2-Hydroxyglutarate Produced by Mutant IDH1 Sensitizes Cells to Ferroptosis,” Cell Death & Disease 10, no. 10 (2019): 755.

[487] J. Lyu, Y. Liu, N. Liu, et al., “CD44-Mediated Metabolic Rewiring Is a Targetable Dependency of IDH-Mutant Leukemia,” Blood 145, no. 14 (2025): 1553–1567.

[488] Z. Zhang, M. Guo, Y. Li, et al., “RNA-Binding Protein ZFP36/TTP Protects Against Ferroptosis by Regulating Autophagy Signaling Pathway in Hepatic Stellate Cells,” Autophagy 16, no. 8 (2019): 1482–1505.

[489] C. Pfirschke, C. Engblom, S. Rickelt, et al., “Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy,” Immunity 44, no. 2 (2016): 343–354.

[490] H. Yang, R. M. Villani, H. Wang, et al., “The Role of Cellular Reactive Oxygen Species in Cancer Chemotherapy,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 266.

[491] H. Wang, Y. Liang, Z. Liu, et al., “POSTN⁺Cancer-Associated Fibroblasts Determine the Efficacy of Immunotherapy in Hepatocellular Carcinoma,” Journal for Immunotherapy of Cancer 12, no. 7 (2024): e008721.

[492] Z. Yuan, Y. Li, S. Zhang, et al., “Extracellular Matrix Remodeling in Tumor Progression and Immune Escape: From Mechanisms to Treatments,” Molecular Cancer 22, no. 1 (2023): 48.

[493] H. Jia, X. Chen, L. Zhang, and M. Chen, “Cancer Associated Fibroblasts in Cancer Development and Therapy,” Journal of Hematology & Oncology 18, no. 1 (2025): 36.

[494] Y. Zhao, Y. Jia, J. Wang, et al., “circNOX4 Activates an Inflammatory Fibroblast Niche to Promote Tumor Growth and Metastasis in NSCLC via FAP/IL-6 Axis,” Molecular Cancer 23, no. 1 (2024): 47.

[495] Z. Wu, X. Lin, Y. Ying, et al., “A Dual-Targeting Strategy to Inhibit Colorectal Cancer Liver Metastasis via Tumor Cell Ferroptosis and Cancer-Associated Fibroblast Reprogramming,” Bioactive Materials 52 (2025): 73–91.

[496] Q. Lu, D. Kou, S. Lou, et al., “Nanoparticles in Tumor Microenvironment Remodeling and Cancer Immunotherapy,” Journal of Hematology & Oncology 17, no. 1 (2024): 16.

[497] X. Meng, Y. Shen, H. Zhao, X. Lu, Z. Wang, and Y. Zhao, “Redox-Manipulating Nanocarriers for Anticancer Drug Delivery: A Systematic Review,” Journal of Nanobiotechnology 22, no. 1 (2024): 587.

[498] W. Tao and Z. He, “ROS-Responsive Drug Delivery Systems for Biomedical Applications,” Asian Journal of Pharmaceutical Sciences 13, no. 2 (2018): 101–112.

[499] H. A. Joshi, R. S. Patwardhan, D. Sharma, S. K. Sandur, P. V. Devarajan, et al., “Pre-Clinical Evaluation of an Innovative Oral Nano-Formulation of Baic Alein for Modulation of Radiation Responses,” International Journal of Pharmaceutics 595 (2021): 120181.

[500] W. Zhou, J. Zhang, W. Chen, and C. Miao, “Prospects of Molecular Hydrogen in Cancer Prevention and Treatment,” Journal of Cancer Research and Clinical Oncology 150, no. 4 (2024): 170.

[501] X. Li, J. Gao, C. Wu, et al., “Precise Modulation and Use of Reactive Oxygen Species for Immunotherapy,” Science Advances 10, no. 20 (2024): eadl0479.

[502] J. Huang, Y. Zhao, K. Zhao, K. Yin, and S. Wang, “Function of Reactive Oxygen Species in Myeloid-Derived Suppressor Cells,” Frontiers in Immunology 14 (2023): 1226443.

[503] Z. Gong, L. Xue, H. Li, et al., “Targeting Nrf2 to Treat Thyroid Cancer,” Biomedicine & Pharmacotherapy 173 (2024): 116324.

[504] S.-L. Li, H.-Y. Hou, X. Chu, et al., “Nanomaterials-Involved Tumor-Associated Macrophages' Reprogramming for Antitumor Therapy,” ACS Nano 18, no. 11 (2024): 7769–7795.

[505] S. J. O'Day, A. M. M. Eggermont, V. Chiarion-Sileni, et al., “Final Results of Phase III Symmetry Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone as Treatment for Chemotherapy-Naive Patients With Advanced Melanoma,” Journal of Clinical Oncology 31, no. 9 (2013): 1211–1218.

[506] M. P. Mehta, P. Rodrigus, C. H. J. Terhaard, et al., “Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases,” Journal of Clinical Oncology 21, no. 13 (2003): 2529–2536.

[507] S. L. Soignet, S. R. Frankel, D. Douer, et al., “United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia,” Journal of Clinical Oncology 19, no. 18 (2001): 3852–3860.

[508] B. Escudier, T. Eisen, W. M. Stadler, et al., “Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma,” New England Journal of Medicine 356, no. 2 (2007): 125–134.

[509] H. M. Kantarjian, C. D. DiNardo, T. M. Kadia, et al., “Acute Myeloid Leukemia Management and Research in 2025,” CA: A Cancer Journal for Clinicians 75, no. 1 (2025): 46–67.

[510] A. Jatoi, N. R. Foster, A. Wahner Hendrickson, et al., “A Phase 2 Trial of Protein Kinase C Iota Inhibition With the Combination of Auranofin and Sirolimus in Patients With Recurrent Ovarian Cancer,” American Journal of Clinical Oncology (2025), https://doi.org/10.1097/COC.0000000000001263.

[511] M. Mastall, P. Roth, A. Bink, et al., “A Phase Ib/II Randomized, Open-Label Drug Repurposing Trial of Glutamate Signaling Inhibitors in Combination With Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma: The Gluglio Trial Protocol,” BMC Cancer 24, no. 1 (2024): 82.

[512] D. A. Sallman, R. S. Komrokji, A. E. Dezern, et al., “Long-Term Follow-Up and Combined Phase 2 Results of Eprenetapopt and Azacitidine in Patients With TP53 Mutant MDS/AML,” HemaSphere 9, no. 7 (2025): e70164.

[513] M. S. Beg, D. Boothman, L. Khosama, et al., “A Phase I/Ib, Multi-Center Trial of ARQ-761 (Beta-Lapachone) With Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Cancer,” Annals of Oncology 30 (2019): v271.

[514] G. K. Abou-Alfa, T. Macarulla, M. M. Javle, et al., “Ivosidenib in IDH1-Mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study,” Lancet Oncology 21, no. 6 (2020): 796–807.

[515] T. A. Yap, N. Daver, M. Mahendra, et al., “Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials,” Nature Medicine 29, no. 1 (2023): 115–126.

[516] M. A. Gouda, M. H. Voss, H. Tawbi, et al., “A Phase I/II Study of the Safety and Efficacy of Telaglenastat (CB-839) in Combination With Nivolumab in Patients With Metastatic Melanoma, Renal Cell Carcinoma, and Non-Small-Cell Lung Cancer,” ESMO Open 10, no. 5 (2025): 104536.

[517] Q. Zhang, Q. Luo, Z. Liu, M. Sun, and X. Dong, “Nano-ROS-Generating Approaches to Cancer Dynamic Therapy: Lessons From Nanoparticles,” Chemical Engineering Journal 457 (2023): 141225.

[518] H. Zhang, Z. Mao, Y. Kang, W. Zhang, L. Mei, and X. Ji, “Redox Regulation and Its Emerging Roles in Cancer Treatment,” Coordination Chemistry Reviews 475 (2023): 214897.

[519] J. Liu, B. Li, L. Li, X. Ming, and Z. P. Xu, “Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy,” Small 20, no. 38 (2024): e2403024.

[520] D. Li, J. He, G. Ding, et al., “Advancements in NADH Oxidase Nanozymes: Bridging Nanotechnology and Biomedical Applications,” Advanced Healthcare Materials 14, no. 8 (2025): e2402785.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm – Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).